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 The dream is just to be simply me, that you are accepted for who you are  
and aren't categorized by…which socks you have or what job or how much  
money you make or if you have HIV   
/Study participant
  
ABSTRACT 
The studies included in this thesis examined experiences of HIV-related stigma among 
persons living with HIV in the current era of efficient treatment. 
Background Human immunodeficiency virus (HIV) has been a stigmatized condition since 
the beginning of the pandemic and people living with HIV who experience HIV-related 
stigma have been found to have lower health-related quality, also after the introduction of 
efficient treatment. HIV-related stigma has also been found to be a barrier to treatment and 
care. HIV has changed from being a deadly disease to a chronic condition where treatment is 
generally available, and people with efficient treatment are at extremely low risk of 
transmitting HIV to others. It is, however, unknown how people who are virally suppressed 
experience stigma related to HIV, and if stigma has consequences for their health-related 
quality of life.   
Aim The overall aim of this thesis was to study self-reported stigma among people living with 
HIV in Sweden in the current era of efficient treatment. Further, the aim was to examine 
validity of the HIV stigma scale and to test the HIV stigma framework in a Swedish context 
where treatment is generally available. 
Methods For measurement of experiences of HIV-related stigma we evaluated a Swedish 
version of the HIV stigma scale in a sample of 193 persons living with HIV in Sweden (44% 
female) (Paper I-III). Psychometric properties of the HIV stigma scale was also analyzed 
using data from people living with HIV in the United States and South India. The HIV stigma 
scale were then used, together with measures of health-related quality of life and adherence to 
treatment, to test hypothesized associations between stigma and lower health-related quality 
of life (as proposed in the HIV stigma framework by Earnshaw and Chaudoir [1]) for people 
living with HIV in a Swedish context (Paper IV). The experience of HIV-related stigma was 
explored using framework approach in analyzing individual interviews with 15 persons who 
were virally suppressed (8 women, 7 men) (Paper V). Health-related quality of life was 
compared to a general Swedish population and to a sample of men living with HIV 1993-
1995 (not included in paper I-V). 
Results The HIV stigma scale was found to be valid in general for measurement of stigma in 
the Swedish context, although some items, mostly belonging to the subscale Disclosure 
concerns had questionable psychometric properties (Paper I-III). To have disclosure concern 
was the aspect of stigma that was prominent among people living with HIV in Sweden (64% 
had disclosure concerns to a higher extent). The hypothesized relations in the HIV stigma 
framework was not confirmed in the Swedish context except for associations between 
internalized stigma and lower emotional wellbeing, and anticipated stigma and lower physical 
functioning (Paper IV). People who were virally suppressed did not think about their HIV 
much in general. Still, some had been treated badly because of their HIV and they anticipated 
rejection or labeling if their HIV got known to others (Paper V). The health-related quality of 
life was found to be lower for people living with HIV in Sweden than for a Swedish general 
population, and equally low as for people living with HIV in Sweden 20 years ago. 
Conclusion Although Sweden is in the front line regarding treatment, findings in this thesis 
indicate that the health-related quality of life seems not to have improved for people living 
with HIV in Sweden. HIV is still a stigmatized condition, even for persons who are virally 
suppressed. A majority of people living with HIV in Sweden have not experienced enacted 
stigma, but it is common to have concerns about when and to whom you should disclose your 
HIV.  
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1 BACKGROUND 
1.1 HIV HISTORY –FROM A WESTERN PERSPECTIVE 
In 1981, the first official reports of what was later known as HIV/AIDS was published in the 
Morbidity and mortality weekly report by the Center for Disease control at the U.S. 
department of health and human services [2, 3]. Four, previously healthy young homosexual 
men, were described to have contracted pneumonia, extensive mucosal candidiasis and 
multiple viral infections. One of them also developed Kaposi’s sarcoma [4]. Conclusions 
drawn at an early stage was that the syndrome could be sexually transmitted [4]. By 1982 the 
U.S. Center for Disease Control recommended to call the syndrome acquired 
immunodeficiency syndrome (AIDS) [5].  
As AIDS was most common in men who had sex with men (MSM), early theories about the 
cause focused on “life style” issues, i.e. multiple sex partners and the syndrome was 
commonly known as the “gay plague” [5]. In Sweden, where the first person was diagnosed 
with AIDS in 1983, AIDS was initially noticed as a limited problem, only affecting gay men, 
and the press did note write much about the new syndrome until 1995, when a boy with 
hemophilia got infected through blood transfusion at a Swedish hospital [6]. In 1983, also 
heterosexual transmission of AIDS was reported and it started to become clear that AIDS was 
not a disease solely affecting gay men but that worldwide, 80% of new infections had been 
heterosexually transmitted, with the highest infection rates in countries in sub-Saharan Africa 
[5].  
1.2 SWEDISH MEDIA REPORTS DURING THE 1980’S 
According to Anna Ljung [6], who wrote a thesis on how Swedish press covered AIDS, 
Swedish media reports on AIDS increased after 1985, with a focus on certain “risk groups”, 
i.e. groups referred to as homo- and bisexual men, prostitutes, drug addicts and African men 
[6]. Drastic actions to prevent infection where suggested (but not implemented), as a 
mandatory tattoo for people who were infected, a certain “license for sex” for those who were 
not infected [6], or to isolate people who were infected on an island [7]. On front page of a 
larger Swedish daily newspaper (“Dagens Nyheter”) in 1987, a picture was displayed of how 
the body of a person who died of AIDS was handled. The body was covered in a black, 
plastic bag with large stickers labeled “smittorisk” (“contagious”). Next to the body two 
physicians were seen, wearing full protective equipment and the article that followed was 
titled “AIDS-epidemi på väg” (“AIDS epidemic on its way”). Ljung [6]concluded that the 
menacing picture of the AIDS epidemic, portrayed in media, had a negative effect on how 
people living with HIV was treated in health care and in society.  
1.3 SWEDISH LAWS AND REGULATIONS 
In Sweden, people living with HIV have legal protection against discrimination, as HIV 
counts as a disability in the law against discrimination (SFS 2008:567). At the same time, the 
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Swedish laws that control people living with HIV have been found to be among the most 
restrictive in the world [8]. HIV was included in the Swedish Law for communicable disease 
control (SFS 2004:168) in 1985 [6], which meant that people living with HIV, among other 
restrictions, became obliged to inform others about the infection if considerable risk of 
transmission occurred. The Swedish Law for communicable disease control made it possible 
to isolate people with HIV against their will and individuals have been convicted of abuse 
and given prison sentences because of not disclosing their HIV status to sexual partners [7]. 
Although the number of persons sentenced to prison each year is low, the consequences for 
the convicted individual are severe, especially for persons who have migrated to Sweden, 
who may be deported to their country of birth after served sentence [7]. 
In later years, based on the growing evidence on the minimal risk of transmission when 
persons are on ART [9, 10], the application of the law has changed, and from 2013 it is up to 
the treating physician to give individual restrictions, based on adherence and treatment results 
[11]. A report released by The Public Health Agency of Sweden in 2018 showed that 
physicians in HIV clinics have good knowledge in general about the minimal risk of 
transmission when persons are on ART. Eighty three percent of physicians had excluded one 
or more patients from the duty to inform sexual partners about their HIV [12].   
The legal position in Sweden is still uncertain [12]. A person who was prosecuted for putting 
other persons in danger in 2013 (through unprotected sexual intercourse) was acquitted due to 
the extremely low risk of HIV transmission. However, a Supreme Court precedence from 
2004 is still directive [12] but the Swedish Supreme Court have granted leave to appeal in the 
2013 case, which might lead to a new precedence [12] (the Supreme Court trial is expected to 
take place in May 2018).       
1.4 KNOWLEDGE AND ATTITUDES REGARDING HIV AMONG THE SWEDISH 
POPULATION  
Knowledge and attitudes regarding HIV in the Swedish population has been regularly 
examined by The Public Health Agency of Sweden since 1987 [13]. In the latest survey, 
performed in 2016, 9 % answered that they would avoid close contact with a person that have 
HIV, compared to 52% that answered that they would avoid close contact in the survey 
conducted 1987. Around 18% in the 2016 survey agreed with the statement that persons with 
HIV should refrain from sexual contacts, compared to 66% who agreed to that statement in 
1987. Although the situation seems to improve the authors of the 2016 report concluded that 
prejudice and stigma around HIV still exist in the Swedish society and that the knowledge 
regarding how treatment prevents HIV transmission is limited in the Swedish population 
[13].  
1.5 HIV IN THE HUMAN BODY 
The biological cause of AIDS was found in 1983 when a new human retrovirus was detected, 
later named HIV (Human immunodeficiency virus) [14]. The HIV virion contains two copies 
of RNA and a set of viral proteins, surrounded by a membrane [15] (Figure 1, right picture). 
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The proteins include enzymes that are essential in the HIV reproduction cycle (Figure 1, left 
picture); the reverse transcriptase that synthesizes RNA into DNA, the integrase that 
integrates viral DNA into the cell genome and the protease that cleaves the virus protein [16] 
before the HIV particle leaves the cell as a new virion.  
 
Figure 1. HIV reproduction cycle.  
By Daniel Beyer, https://commons.wikimedia.org/wiki/File:HIV_gross_cycle_only.png, 
translated to English by Raul654, https://commons.wikimedia.org/wiki/User:Raul654, 
License CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/ 
 
1.5.1 Routes of transmission 
The most common route of HIV transmission is when virus in semen or mucosal surfaces is 
transmitted through sexual contact [17]. The virus can also enter the human body through 
blood or be transmitted from mother to fetus/infant [17]. HIV cannot be transmitted through 
body fluids like saliva or tears. Without treatment the probability of acquiring HIV is highest 
through blood transfusion and mother-to-child transmission and regarding sexual route of 
transmission the risk is highest for receptive anal intercourse [18]. High viral load, as seen in 
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the acute and late phase (Figure 2), is a factor that may increase HIV transmission. The risk 
of acquiring HIV is also higher if one has genital ulcer disease [18]. 
1.5.2 HIV and the immune system 
The major target cell for the HIV virion is the CD4
+
 T cell, which have a central role in the 
immune system.  The virus disseminates rapidly within the first weeks after transmission (red 
graph in Figure 2) leading to acute HIV syndrome for a majority of people with HIV with flu-
like symptoms [17]. In the absence of treatment, virus levels typically peak after three to four 
weeks and then declines and reach a steady state (Figure 2).  As the blue graph (Figure 2) 
shows, persons with HIV progressively lose CD 4
+
 T cell in absence of treatment, which 
ultimately leads to opportunistic infections characterized as AIDS [17].   
 
Figure 2. Graph showing HIV copies and CD4 counts in a human over the course of a 
treatment-naive HIV infection. By Jurema Oliveira - Based on Figure 1 in Pantaleo, G et al. 
[19], https://commons.wikimedia.org/wiki/Category:HIV_time_course , License CC BY-SA 
3.0 https://creativecommons.org/licenses/by-sa/3.0/ 
1.6 ANTIRETROVIRAL TREATMENT 
The introduction of combined antiretroviral treatment (ART) in 1996 made a dramatic change 
in morbidity and mortality related to HIV. HIV has changed from being a deadly disease to a 
chronic condition with life-expectancy of people living with HIV comparable to uninfected 
where treatment is generally available [20]. In combined antiretroviral treatment, different 
pharmaceuticals are combined to inhibit different steps of the viral life-cycle; i.e. the reverse 
transcriptase, integrase and protease (Figure 1) [21]. Although the first available treatments, 
had severe medical side effects, modern antiretroviral treatment are associated with minimal 
side effects [22] 
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According to Swedish treatment guidelines antiretroviral treatment is considered to be 
effective if the following criterions are fulfilled if viral load and adherence to treatment is 
monitored 2-4 times per year [20] and:  
- Viral load of HIV RNA in blood plasma is countinously <50 copies/ml, at two 
succesive measurements, 3-6 months apart[20]. 
- The person with HIV maintains a continously high adherence to treatment [20] 
1.6.1 Risk of HIV transmission when persons are virally suppressed 
In 2008 the Swiss AIDS Commission announced what thereafter has been reffered to as the 
Swiss statement; that people living with HIV who are on effective treatment should not be 
considered infectious through sexual  contact (if certain criteria are fulfilled) [23]. The HIV 
prevention  trials network (HPTN 052) study then provided more evidence regarding the risk 
of HIV transmission, when persons with HIV were virally suppressed [24]. The study 
followed 1763 couples, included 2007-2010, where one partner was HIV-positive and the 
other partner HIV-negative (i.g. a serodiscordant couple) at the beginning of the study. 
Couples where randomized into two groups, where the HIV-positive partner either got ART 
from the start, regardless of CD 4 levels, or received ART when CD 4 count whent below 
250 cells/ml. All couples were adviced about the use of condoms. Early ART was associated 
with a 96% reduction in the risk of transmission through sexual contact compared to later 
start with ART [9, 25]. A recent meta-analysis pooled results from the HPTN 052 study with 
results from five other similar studies and showed that among 2848 serodiscordant couples 
where the person with HIV was virally suppressed, HIV had not been transmitted in any 
cases (rate of transmission = 0 per 100 person-years (95%CI=0–0.01)) [10]. 
The Public health Agency of Sweden released a statement in 2013 regarding risk of HIV 
transmission, based on the HPTN 52 study in combination with other observational studies 
[11, 20].  The risk of HIV transmission through sexual intercourse was stated to be minimal if 
the person with HIV where on effective ART and a condom was used throughout intercourse. 
The risk was considered to be very low also if a condom was not used. The risk of 
transmission through needle sharing when injecting drugs where considered to markedly 
reduced if the person with HIV where on effective ART [20]. The risk of mother-to-child 
transmission was considered to be less than 0.5% if the pregnant women had effective ART 
well in advance before the baby was born [20]. 
1.6.2 A residual problem in Sweden with late HIV diagnosis 
Although Sweden has achieved the 90-90-90 goals [26] with a very high proportion of people 
living with HIV being diagnosed and efficiently treated, a key residual problem in the 
Swedish HIV epidemic have been that persons with HIV are diagnosed late (when CD4 
counts <350 cells/ml or the person already had been diagnosed with an AIDS defining 
illness) [27, 28]. Johanna Brännström [29] concluded in her thesis about late HIV diagnosis 
in Sweden that more than half of Swedish patients with HIV were diagnosed late and that 
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older age and foreign origin was the two most important factors increasing the risk of late 
diagnosis.  
1.7 A GLOBAL PERSPECTIVE 
Great efforts have been and still are made to increase the access to antiretroviral treatment all 
over the world and in 2017 approximately 20.9 million out of the estimated 36.7 million 
people living with HIV worldwide had access to antiretroviral therapy. The majority of 
people diagnosed with HIV are living in Eastern and Southern Africa (19.4 million people, 
59% women) and the rest is distributed as follows; 6.1 million in Western and Central Africa, 
5.1 million in Asia and the Pacific, 1.8 million in Latin America, 310,000 in the Caribbean, 
230,000 in Middle East and North Africa, 1.6 million in Eastern Europe and Central Asia and 
2.1 million in Western and Central Europe and North America [30].  
1.8 THE SWEDISH CONTEXT 
Around 10,000 people have been diagnosed with HIV in Sweden since the beginning of the 
pandemic and 7532 were registered in clinical care in March 2018 according to the Swedish 
database InfCare HIV [31], which gives a prevalence of approximately 0.07%. Of these 39% 
were women and 61% men, 36% were born in Sweden and 64% in other countries. Route of 
transmission, as documented in InfCare HIV, was 31.1%  homo/bisexual, 51% heterosexual, 
5.3% intravenous drug use, 1.5% blood products, 2.9% mother-to-child transmission and 
5.9% other/unknown [31]. When data was collected for this thesis in 2013 the number of 
people registered in clinical care was 6205 (38% female, 59% born in other countries than 
Sweden [31]. 
Antiretroviral therapy is available, without any out-of-pocket costs, to all people living with 
HIV in Sweden and Sweden was the first country to achieve the Joint United Nations 
Program on HIV/AIDS (UNAIDS) 90-90-90 goal; that 90% of people living with HIV in a 
country should be diagnosed, 90% of these under treatment and 90% of these have an HIV 
RNA level of <50 copies/ml [32]. In March 2018 97.4% of persons registered in clinical care 
were under treatment and 94.7% of those were virally suppressed (HIV viral loads <50 
copies/ml) [31].  
1.9 CENTRAL CONCEPTS AND FRAMEWORKS  
1.9.1 HIV-related stigma 
In a statement presented for the United Nations general assembly in 1987, Jonathan M. Mann 
(director of the special program of AIDS at the World health organization) referred to, what 
he called, the third epidemic of AIDS [33]. The first epidemic was, according to Mann, the 
spread of the virus, followed by the second epidemic of people being diagnosed with AIDS. 
Following these epidemics came, relentlessly, the third epidemic, consisting of the economic, 
social, political and cultural response and reaction to AIDS [33].  Since the beginning of the 
pandemic, researchers have been tracking this third epidemic and often, but not always, 
referred to it as the stigma around HIV and AIDS.  
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1.9.1.1 The origin of the concept of social stigma 
The word stigma is originally Greek and refers to a mark made on the skin by hot iron or by 
cutting/pricking, as a symbol of infamy [34]. When stigma is used in the context of HIV it, 
however, refers to a social stigma. The understanding of social stigma is often based on the 
work of E. Goffman [35] who described stigma as “an attribute that is deeply discrediting, 
that reduces the bearer from a whole person to a tainted, discounted one” (p 10-11). Based on 
his own experience of working within psychiatric hospitals, and with certain groups as people 
with a criminal background, he described the process when certain groups and individuals are 
being pointed out as abnormal in society. Goffman discussed the difference between a visible 
and a concealable stigma, where a visible stigma was thought to have a direct negative effect 
on the identity of the person who is stigmatized whilst an concealable stigma constantly 
would put the person in situations where he or she must decide whether to disclose the 
stigmatized attribute or not.  
1.9.1.2 Towards a definition of HIV-related stigma 
Although Goffman’s work “Stigma; notes on the management of spoiled identity” [35] have 
been proven useful in explaining social mechanisms related to a wide range of diseases, the 
concept of stigma have been found difficult to define [36, 37]. As Goffman described 
complex processes that appear when certain characteristics are found to be deviant, 
conceptual definitions of social stigma have often excluded parts of the process [36]. Stigma 
has, for example been defined as a characteristic [36], instead of a social process and it is 
common to separate stigma and discrimination [38], although discrimination can be 
understood as a part of the process of social stigma [37]. 
A comprehensive definition of social stigma in general has been presented by Link and 
Phelan  [36], who stated that “stigma exists when elements of labeling, stereotyping, 
separating, status loss and discrimination co-occur in a power situation that allows the 
processes to unfold” (p382) [36]. Based on the definition by Link and Phelan [36] a 
conceptual framework for HIV-related stigma has been developed by Mahajan and 
colleagues [37]. However, there are also other frameworks for HIV-related stigma available 
and there is still a lack of consensus regarding how HIV-related stigma should be defined. 
1.9.1.3 An addition of critical theory 
A later contribution to theoretical frameworks around HIV-related stigma have been that 
HIV-related stigma not only occurs and is maintained on an individual level but also on a 
structural level within political and economic processes [39]. Parker and Aggleton [39] 
argued, inspired by Michel Foucault and Pierre Bourdieu, that power on a structural level not 
only maintains stigma but that stigma, with its processes of labelling and categorization also 
constitutes and helps to maintain structures of power. The Foucauldian perspective also 
brought a certain perspective on how stigma can be reduced, since Foucault throughout his 
work, put power in relation to resistance from the oppressed [40]. According to Parker and 
Aggleton [39] the most effective and powerful responses to the epidemic have taken place 
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when affected groups have mobilized themselves to fight back. Parker and Aggleton 
therefore requested interventions that may unleash the power of resistance in the stigmatized 
groups of people living with HIV [39]. 
1.9.1.4 How stigma is defined in this thesis 
This thesis is not based on one single definition of HIV-related stigma. A theoretical 
framework (the HIV stigma framework, presented below) was used to examine individual 
experiences of HIV-related stigma and the HIV stigma scale (also presented below) was used 
for measurement of experiences of HIV-related stigma. The HIV stigma framework and the 
HIV stigma scale are based on slightly different understandings of how HIV-related stigma is 
constructed and maintained in society. 
1.9.2 The HIV stigma framework 
Earnshaw and Chaudoir [41] have, in a review of stigma measurements, called for clarity 
regarding conceptualization and measurement of HIV-related stigma. According to Earnshaw 
and Chaudoir [41] it is essential to distinguish between different aspects of how HIV-related 
stigma is experienced by the individual living with HIV, since different aspects of stigma not 
necessarily are associated with the same aspects of health-related quality of life.  
Earnshaw and Chaudoir [41, 42] have presented a theoretical framework, the HIV stigma 
framework, that suggest that individual level stigma mechanisms for both people living with 
HIV and people who are uninfected  can be elicited by the existence of HIV as a stigmatized 
“mark” [41]. These individual stigma mechanisms are all psychological responses to the 
knowledge that HIV is a socially devalued characteristic [41]. The HIV stigma framework 
was based on an understanding of stigma from Goffman [35], Link and Phelan [36] and 
Parker and Aggleton [39]. But in contrast to how stigma was defined by Link and Phelan 
[36], Earnshaw and Chaudoir (inspired by Deacon [43]) separated stigmatizing believes (i.e. 
Stigma in Figure 3) from stigmatization processes (i.e. Mechanisms in Figure 3).   
 
Figure 3. Earnshaw and Chaudoir’s [41] HIV stigma framework (adapted from Fig 1. Model 
of HIV stigma mechanisms [41]) 
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The first mechanism for people living with HIV proposed by Earnshaw and Chaudoir [41] 
was enacted stigma; defined as when people living with HIV believe that they have 
experienced prejudice and discrimination from others in their community. The second 
mechanism, anticipated stigma, was defined as when people living with HIV anticipate 
experiencing prejudice and discrimination in the future [41]. Finally, the third stigma 
mechanism internalized stigma, represented when people living with HIV endorse negative 
feelings and believes associated with HIV about themselves [41]. Earnshaw et al have 
hypothesized that these stigma mechanisms could have different outcomes related to health 
and wellbeing for people living with HIV [42] (presented in Figure 4). In the HIV stigma 
framework enacted stigma along with anticipated stigma, was hypothesized to have a 
negative effect on physical aspects of quality of life, since both the fear of and experience of 
being stigmatized have been found to be stressful for the individual. Anticipated stigma was 
also hypothesized to affect medical adherence, since the HIV diagnosis can be revealed if 
someone recognize the person when he or she visit the hospital for a clinical appointment or 
takes his/her medicine. Internalized stigma was hypothesized to have a negative impact on 
the affective and emotional aspects of wellbeing for the individual, and also that a person 
with internalized stigma would feel less worthy than others and therefore not take their 
medicine or attend medical appointments. All these relations except the hypothesized path 
between anticipated stigma and behavioral health and wellbeing, have been confirmed in a 
North American context [42]. 
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Figure 4. Earnshaw and Chaudoir’s HIV stigma framework for people living with HIV [41, 
42] (adapted from Fig 1. Hypothesized associations between HIV stigma mechanisms and 
health and wellbeing among PLWH [42]) 
1.9.3 Berger’s HIV stigma scale 
There are numerous patient-reported outcome instruments that measure different aspects of 
HIV-related stigma. In a review of measurements for HIV-related stigma, Earnshaw and 
Chaudoir [41] found sixteen instruments designed for measurement of how individuals living 
with HIV experienced stigma; four of these measure and differentiate between all three of 
their proposed stigma mechanisms (enacted, anticipated and internalized stigma). Of these 
four instruments, the HIV stigma scale by Berger et al [44] was the one most widely used 
[41].  
The items in the HIV stigma scale were based on extensive literature review of research 
regarding social stigma in general and HIV-related stigma in specific. Based on major 
sources on HIV-related stigma, published between 1989 and 1993 Berger et al [44] developed 
a conceptual model of perceived stigma in people with HIV (Figure 5). Items were reviewed 
by experts on stigma from the disciplines of nursing, psychology and sociology and focused 
on content; special efforts were made to ensure that all aspects of HIV-related stigma that the 
authors could find in the literature were covered by the items. Items found to be irrelevant or 
in need of major revision were excluded. The questionnaire was then tested with exploratory 
factor analysis and a four-factor structure emerged. The authors interpreted the factors as (1) 
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personalized stigma (2) disclosure concerns, (3) concerns about public attitudes and (4) 
negative self-image [44].  
 
Figure 5. Berger’s model of perceived stigma in people with HIV [44] 
 
1.9.4 Disclosure 
The concept of disclosure is central within theories that regard HIV-related stigma [45] (and 
concealable stigmatized identities in general). Often disclosure, as in being open with one’s 
HIV status, is presented as something desirable, with benefits both for the individual with 
HIV and for the society, from a perspective of HIV prevention [38, 46].  A study on 
concealable stigmatized identities in general (but not on HIV), however, showed that for 
persons who had made their concealable stigmatized identity (e.g. mental condition, previous 
experience of rape or abuse, previous drug use) a central part of their identity had increased 
psychological distress [47].  
Mayfield Arnold and colleagues [48] have presented three different pathways for the choice 
people living with HIV make regarding disclosure; (1) disclosure to everyone, (2) disclosure 
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to some and (3) disclosure to no one. According to Mayfield Arnold et al [48] the pathway of 
disclosure to some is the most common pathway among people living with HIV, as well as 
being the most complex one. 
1.9.5 Health-related quality of life 
Health-related quality of life is a multidimensional concept that usually involves emotional 
and physical aspects of the quality of life, as well as cognitive functioning and aspects 
regarding family and relations [49]. For people with HIV, in addition to the aspects generally 
included in the health-related quality of life dimensions, the following specific areas have 
also been found to be of significance; fatigue, pain, nausea and vomiting, sleep issues, sexual 
functioning and issues about disclosure; however, many instruments, including HIV-specific 
ones, do not cover all of these areas of significance [50, 51]. 
More than 20 years ago, between 1993 and 1995, Eriksson and colleagues [52] found that 
Swedish males living with HIV had significantly worse health-related quality of life, 
compared to a general Swedish male population. Both physical and emotional aspects of 
health-related quality of life were measured, including relations to family and partner as well 
as sexual functioning, using the Swedish health-related quality of life questionnaire (SWED-
QUAL) [53]. Eriksson et al. [52] showed that especially dimensions of emotional well-being 
were affected.  
1.9.6 Associations between HIV-related stigma and health-related quality of 
life 
In reviews on correlates to HIV-related stigma that cover research in an American context up 
until 2007, HIV-related stigma has been found to have negative correlations to health-related 
quality of life, both to physical [54] and emotional [54, 55] aspects. HIV-related stigma has 
also been associated with decreased social support, lower income and lower age [54]. Also in 
later years, experiences of HIV-related stigma have been found to be associated with 
negatively affected quality of life for people living with HIV in a wide range of different 
countries [56-69]. In meta-analyses covering 64 publications from 1996-2013 associations 
were found between HIV-related stigma and higher rates of depression and lower social 
support. Weaker relationships were also found between HIV-related stigma and overall 
quality of life, physical health, anxiety, emotional and mental distress and sexual risk 
practices [70]. 
1.9.7 Associations between HIV-related stigma and antiretroviral adherence 
Worldwide, stigma around HIV has been identified as a barrier to HIV testing and to care 
[38] and when UNAIDS has launched strategies for HIV prevention and treatment, ending 
HIV-related stigma has been high on the agenda [71]. Non-disclosure because of fear of 
stigma has been found to be a barrier to antiretroviral treatment [72-75] and internalized 
stigma has also been found to undermine people’s adherence to treatment [72, 76]. However, 
a recent meta-analyses performed by Rueda et al [70] found no statistically significant 
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correlation between HIV-related stigma and adherence when bivariate results were pooled. 
But when potential confounders were accounted for in pooled multivariate analyses the 
results showed that people with experiences of HIV-related stigma were 32% less likely to be 
adherent to antiretroviral treatment [70]. 
1.10 RECENTSTUDIES ABOUT THE LIFE SITUATION OF PEOPLE LIVING 
WITH HIV IN SWEDEN 
In a recently published thesis, Desireé Ljungcrantz [77] has analyzed contemporary 
experiences of life with HIV. According to Ljuncrantz, the social dimensions of HIV are still 
severe, despite the favorable medical outcomes for people living with HIV. To become an 
HIV patient, for example, was found to be a performative process which was not optional for 
the individual. Through verbal and written information where the individual is referred to as 
HIV-infected, and through being included in a medical record and receiving HIV medical 
care the person with HIV becomes an object, according to Ljungcrantz, of care and control 
[77]. Although HIV was not described as a big factor in life for the persons interviewed, HIV 
became an obstacle in certain contexts; i.e. being part of a cooking team, bathing in a pool, or 
flirting in a bar, since other people’s violent responses created negative experiences for the 
individual [77].  
Health-related quality of life has been investigated among children living with HIV in 
Sweden. Rydström and colleagues [78-81] found that both children and their legal guardians 
rated the children’s health-related quality of life as good but that they had concerns about 
disclosing their HIV to others. HIV could make daily life difficult; especially regarding the 
risk of being exposed to stigma [79-81] and experiences of HIV-related stigma was 
negatively associated to health-related quality of life [82]. The Swedish youths, living with 
HIV described how they refrained from sexual relations in order to maintain control over who 
that knew about their HIV. Some also questioned the obligation to inform potential sexual 
partners and said that the Swedish Law for communicable disease control needed to be 
changed [81]. 
The Public Health Agency of Sweden has also studied the health-related quality of life of 
people living with HIV in Sweden in the recent survey “Living with HIV in Sweden”, 
performed in cooperation with a research group coordinated by Anna Mia Ekström [83]. The 
participants (1096 people living with HIV in Sweden, 29% female) reported their overall 
quality of life on a scale from 0-10, where higher values indicated better quality of life. 
Values of 7-8 were reported by 36% and 9-10 by 24%; the overall quality of life was thus 
regarded as good in general. However, almost one in five had not told anyone about their 
HIV and two aspects of HIV-related stigma (to have concerns about public attitudes and to 
have a negative self-image) was associated with a lower quality of life [83]. 
In the survey Living with HIV in Sweden, 49% of participants reported being sexually 
dissatisfied [83]. A majority (88%) of participants perceived the obligation to disclose one’s 
HIV to a potential sexual partner as a barrier to engage in sexual relations and finding a long-
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term partner [83]. Regarding those who were sexually dissatisfied, no significant difference 
was found between women, non-heterosexual men and heterosexual men [84]. 
1.11 TO LIVE WITH HIV WHEN HIV HAS BEEN “NORMALIZED” 
From a biomedical perspective, it is clear that antiretroviral treatment has improved the lives 
of people living with HIV who have access to it [85-88]. Where antiretroviral treatment is 
generally available, HIV is now considered a chronic disease or long-term condition like 
many others [85, 87].  When I started my doctoral project in 2012, it was relatively unknown 
whether this biomedical normalization of HIV also would change how people living with 
HIV experienced their condition and further research was requested on what it meant to be 
virally suppressed [89].  
Although some argued that the stigma around HIV would decrease when HIV was 
constructed as a chronic disease [90, 91], being on antiretroviral treatment has, on one hand, 
been found to, paradoxically, increase stigma, by making HIV visible (through daily 
medicine and visits to HIV-clinics) [92]. The years following the introduction of effective 
treatment have, on the other hand, also been referred to as “the big silence”, where people 
have stopped talking about HIV in general [93]. Questions remains whether antiretroviral 
treatment actually have made HIV less stigmatized, or if the treatment only made it possible 
for people with HIV to conceal their condition, thus avoiding enacted stigma [92].  
During the last years, when I have been working with this thesis, research has been published 
showing that the subjective experience of living with HIV not necessarily improves when 
treatment becomes more effective [86-88]. A study performed in the United Kingdom 
showed ambiguous experiences, where HIV as a normalized condition existed alongside 
experiences of stigma, fear and shame [87].  
In this thesis I have examined contemporary experiences of HIV-related stigma in Sweden, 
where treatment is generally available. I have been interested in if, and in that case, how 
people living with HIV in Sweden today experience HIV-related stigma and also if 
previously found correlations between stigma and lower health-related quality of life still 
occur when antiretroviral treatment is generally available.  
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2 AIMS 
The overall aim of this thesis is to study self-reported stigma among people living with HIV 
in Sweden in the current era of efficient treatment. Further, the aim was to examine validity 
of the HIV stigma scale and to test the HIV stigma framework in a Swedish context where 
treatment is generally available.  
The specific study aims were: 
To evaluate the psychometric properties of the HIV stigma scale in a Swedish context with 
regard to construct validity, data quality and reliability (Paper I). 
To develop a substantially shorter version of the HIV Stigma Scale with psychometric 
properties retained from the full-length scale (Paper II). 
To examine whether items in the HIV Stigma Scale function differently with regard to gender 
and cultural background (Paper III). 
To test the tenets of the HIV stigma framework and its potential covariates for persons living 
with HIV in Sweden (Paper IV). 
To explore the experience of HIV-related stigma among people living with virally suppressed 
HIV in Sweden and to explore how these experiences correspond to the stigma mechanisms 
for people living with HIV in Earnshaw and Chaudoir’s HIV stigma framework [41].  (Paper 
V). 
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3 METHODS 
3.1 GENERAL STUDY DESIGN 
My overall doctoral project was a mixed methods study, mainly consisting of a cross-
sectional survey with people living with HIV in Sweden and a series of individual interviews 
with persons who were virally suppressed. Results from the cross-sectional survey have been 
published in four papers (Paper I-IV, republished in the later part of this thesis). Results from 
the interviews are published in this thesis as a manuscript (Paper V). Table 1 shows an 
overview over the papers included in this thesis, with design, instruments, participants and 
analytical methods. Psychometric properties of the HIV stigma scale [44] was examined in 
Paper I-III. The HIV stigma scale was then used in an empirical assessment of the HIV 
stigma framework in the Swedish context [41] (Paper IV) and the HIV stigma mechanisms 
[41] were explored in a qualitative interview study (Paper V).  
 
Table 1. Overview over papers included in the thesis 
Paper Design Instruments Participants Analytical 
method 
1 
Cross-sectional 
survey study 
The HIV stigma 
scale 
 
132 PLWH* in Sweden 
(complete answers to 
the HIV stigma scale) 
 
Classical test 
theory 
II The HIV stigma 
scale 
 
132 PLWH in Sweden 
(complete answers to 
the HIV stigma scale) 
 
Classical and 
modern test 
theory,  Item 
reduction 
 
 
The 12-item 
version of the 
HIV stigma scale 
 
880 PLWH in Sweden 
(complete answers to 
the 12-item HIV stigma 
scale) 
 
III The HIV stigma 
scale 
193 PLWH in Sweden 
660 PLWH in the US 
250 PLWH in South 
India 
Modern test 
theory, DIF-
analysis 
IV The HIV stigma 
scale, SWED-
QUAL, measures 
of viral load 
 
173 PLWH in Sweden Partial least 
squares 
structural 
equation 
modelling  
V Interview study Individual in-
depth interviews 
15 Swedish persons 
with virally suppressed 
HIV 
Content analysis 
with framework 
approach 
*People living with HIV in Sweden 
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3.2 INSTRUMENTS 
3.2.1 The Swedish version of the HIV stigma scale 
Berger’s HIV stigma scale [44] was translated to Swedish before I entered the project. The 40 
items were translated independently from English to Swedish by three members of the 
research group. The three translated versions were compared and discussed and merged into a 
Swedish version of the HIV stigma scale, which was reviewed by a bilingual consultant. 
Minor changes were made before the items were translated back to English by a professional 
translator. Additional small changes were then conducted to ensure that the Swedish version 
of the items matched the English version. Cognitive interviews had been performed with a 
purposeful sample of people living with HIV in Sweden (7 men, 2 women, 3 born in Sweden, 
6 born in other countries) and the participants had found the items relevant and 
comprehensive in general. 
Appendix 1 shows the HIV stigma scale as it appeared in the questionnaire. The 40 items in 
the HIV stigma scale were statements that the participants could agree or disagree with on a 
four-point Likert scale (strongly disagree, disagree, agree, and strongly agree). There was no 
response alternative for “not applicable” or “do not want to answer”. The last seventeen items 
in the questionnaire assume disclosure of one’s HIV status, at least to some extent and prior 
to item 24 a text encouraged participants to imagine the situation, even if it had never 
happened to them. Response alternatives and the text prior to item 24 matched the original 
version of the HIV stigma scale [44].  
3.2.2 SWED-QUAL 
SWED-QUAL is a Swedish questionnaire designed to measure health-related quality of life. 
The instrument was developed by Brorsson, Ifver and Hays [53] using items from the US 
Medical Outcomes Study [94-96]. The questionnaire consists of 63 items that form two 
single-item and 11 multi-item scales, which are measures of different aspects of health-
related quality of life. The scales with example of item in respective scale are shown in Table 
2. Each item had a corresponding Likert scale with response alternatives and the responses 
for each item belonging to a scale were transformed into 0-100 scale indexes, with higher 
scores representing better health-related quality of life for all scales. 
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Table 2. Scales in SWED-QUAL with sample items. 
Scale (number of items) Sample item 
Physical functioning (7) Is your health today good enough that you can do the 
following activities? 
a. Streneous activities. e.g., heavy manual work, 
strenuous sports 
Mobility (1) When you have errands outside your home, does someone 
have to assist you because of your health? 
Satisfaction with physical 
ability (1) 
How satisfied are you with your physical ability to do 
everything you want to do? 
Pain (6) Have you been bothered by aches and pain during the last 
week? 
Role limitation because of 
physical health (3) 
How often have your normal activities been interfered with 
because of your physical health during the last week? 
Emotional wellbeing: 
Positive effect (6) 
Do you agree or disagree with the following statements 
concerning your feelings during the last week? 
- I have felt harmony 
Emotional wellbeing: 
Negative effect (6) 
Do you agree or disagree with the following statements 
concerning your feelings during the last week? 
- I have felt sad 
Role limitation because of 
emotional health (3) 
How often have your normal activities been interfered with 
because of emotional problems during the last week? 
 
Sleep (7) Do you agree or disagree with the following statements 
concerning your sleep during the last week 
- I slept poorly 
Satisfaction with family 
life (4) 
Think about your family. How satisfied are you with the 
following aspects? 
- Cohension and mutual understanding 
Relation to partner (6) The following statements concern your relationship with your 
spouse or partner 
- We can talk with each other about almost everything 
Sexual functioning (4) Do you agree or disagree with the following statements? 
- I lack sexual interest 
General health perception 
(9) 
Do you agree or disagree with the following statements 
concerning your general health? 
- My health is as good as others my age 
 
  
3.3 DATA SOURCES 
The studies in this thesis are primarily based on two data collections within the project Stigma 
and quality of life for people living with HIV, which I have performed in collaboration with 
supervisors and colleagues; a cross-sectional survey investigating Stigma and health-related 
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quality of life for people living with HIV (paper I-IV) and a set of in-depth interviews (paper 
V). Data for participants in the survey was also retrieved from the national quality assurance 
registry InfCare HIV [97]. The 12-item version of the HIV stigma scale developed in paper II 
was used in the nation-wide survey Living with HIV in Sweden performed on behalf of the 
Public Health Agency of Sweden [83]; data from Living with HIV in Sweden was used to 
assess psychometric properties of the 12-item version of the HIV stigma scale (Paper II). In 
collaboration with researchers from the United states and India we performed secondary 
analyses (paper III) on the data that we had collected using the 40-item HIV stigma scale in 
combination with data collected with the HIV stigma scale in the US [98, 99] and South India 
[100].  
3.3.1 Quantitative data  
3.3.1.1 Stigma and quality of life for people living with HIV  
A cross-sectional survey was distributed at the Karolinska University Hospital in Stockholm, 
Sweden from March through September 2013. In this thesis I will, from now on, refer to this 
survey as the Stigma and quality of life survey. 
3.3.1.2 Inclusion criteria 
Inclusion criteria were: (1) diagnosis with HIV and (2) 18 years of age and older (3) not first 
appointment at the clinic. We aimed to include a sample that was representative for the 
population of people living with HIV in Sweden, regarding gender, route of transmission and 
country of birth. The group of people living with HIV that were listed at the clinic when data 
collection took place reflected the population people living with HIV in Sweden regarding 
gender, route of transmission and country of birth. We therefore concluded that a consecutive 
inclusion of participants at that clinic would render a sample that was representative for 
people living with HIV in Sweden, except for that an overall majority of the participants 
would be living in an urban area.  
3.3.1.3 Exclusion criteria 
If a professional translator was needed for participation, but had not been booked, participants 
were excluded from the study. Individuals were also excluded if a nurse or physician opposed 
participation. Some females were already included in another ongoing study at the clinic and 
were therefor excluded from our survey.  Some individuals, who were imprisoned for 
unknown reason, came to the clinic in handcuffs and with guards and were counted as 
excluded.  
3.3.1.4 The questionnaire 
The questionnaire, labeled “Questions about your health and life situation”, consisted of the 
Swedish health-related quality of life questionnaire (SWED-QUAL) [53] and Berger’s HIV 
stigma scale [44] (Appendix 1). The following questions were also included; “how old are 
you?”, “are you male or female?”, “in what country are you born?”, “what education best 
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applies to you?” and “how important is religion to you?”  The questionnaire was available in 
Swedish and English and took approximately 30-45 minutes for persons who were fluid in 
Swedish or English to complete.  
3.3.1.5 Strategies to enable participation 
As a large proportion of eligible participants were not fluid in Swedish or English we had 
different alternatives prepared for how participants could be assisted when completing the 
questionnaire. Participants could either complete the questionnaire together with a 
professional translator or fill out the questionnaire with assistance from me or one of two 
research assistants involved in the data collection. We then sat down with the participant in a 
private room at the clinic and completed the questionnaire as a structured interview. The 
participant could ask questions, both about the meaning of certain words, but also about the 
structure of the questionnaire and response alternatives.  
3.3.1.6 Procedures   
From March to the end of June 2013 data collection was conducted on 26 different dates. On 
a day with data collection all persons that visited the clinic for a scheduled appointment, that 
matched inclusion criteria, were considered to be eligible for inclusion. I and one or two 
research assistants sat at a table near the reception and eligible participants were informed by 
the receptionist that we wanted to ask them to participate in a study. We gave eligible 
participants information about the study and gave interested participants written information 
about the study (Appendix 2) and a printed copy of the questionnaire. Participants could then 
sit down in the waiting room and complete the questionnaire before and/or after their 
appointment. Although that was not out initial intention, some participants wanted to take the 
questionnaire home and send it in by mail. We then started providing participants with 
prepaid envelops so that they could mail questionnaires to us.  
Fifty two individuals were excluded from the study, as summarized in figure 6. One hundred 
and twenty-three individuals declined participation (i.e. worried about secrecy, lack of time) 
and 40 individuals were not included due to administrative reasons (i.e. we did not have time 
to help them with the questionnaire, because we helped someone else). The response rate 
(44%) was calculated as individuals who returned a questionnaire (n=197) compared to 
eligible participants (n=441).      
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Figure 6. Flow chart over the process of inclusion in the Stigma and quality of life survey. 
3.3.1.7 InfCare HIV 
InfCare HIV is a national quality assurance registry, linked to the medical record, containing 
socio-demographic (gender, age, country of birth, estimated country of transmission, route of 
transmission) and biological data. For all participants included in the Stigma and quality of 
life survey that returned a questionnaire, the following information was retrieved from 
InfCare HIV; time point of first positive HIV serology, gender, route of transmission, CD4 
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cell count (lowest and most recent value), HIV viral loads (VL) and information about 
antiretroviral treatment. Patients were considered to be non-adherent to treatment if they had 
one viral one VL > 150 copies/ml or two or more consecutive VL > 50 copies/ml within the 
last 2 years of the condition with treatment ongoing at least 6 months prior to the evaluation 
period [101]. 
3.3.2 Qualitative interviews  
Fifteen participants who were durably virally suppressed were recruited through purposeful 
sampling at the same clinic as where the survey was performed; we aimed to recruit a 
heterogeneous sample, regarding age, gender and country of origin. Individual face-to-face 
interviews were performed in conversational style by me (13 interviews) or by co-author 
Galit Zeluf (2 interviews). We had designed a schematic interview protocol, with topics 
aimed to frame the experience of HIV-related stigma, which we used if the participant did not 
talk about a topic spontaneously. Follow-up questions like “can you tell me more about that” 
and “how did you feel about it” were used as probes. Interviews were audio recorded and 
lasted between 23 and 129 minutes. 
3.3.3 Data retrieved for secondary analyses  
3.3.3.1 Living with HIV in Sweden 
The study Living with HIV in Sweden was a nationwide survey on health-related quality of 
life of people living with HIV in Sweden, performed on behalf of the Public Health Agency 
of Sweden [83]. Data was collected 2013-2014 at 15 healthcare units for infectious diseases 
in Sweden, accounting for 75% of HIV care in the country, and at two needle and syringe 
exchange clinics [83]. The study Living with HIV in Sweden used the 12-item version of the 
HIV stigma scale that we had developed (paper II) to measure HIV-related. Item-level data 
from the participants that had answered all 12 items in the HIV stigma scale (n=880) was 
used in paper II in this thesis to evaluate the psychometric properties of the abbreviated 
instrument.    
3.3.3.2 The Indian and United States cohorts 
In 2013 we started collaboration with researchers from University of Washington, Dr Deepa 
Rao and Professor Lisa Manhart. Since they both had access to data collected with the HIV 
stigma scale, we decided to perform secondary analysis on our combined datasets. Since I 
was responsible for performing the analyses, I received their item-level data collected with 
the HIV stigma scale, together with a limited amount of sociodemographic variables. Gender, 
and to some extent age, were the only variables that were comparable over all three cohorts.  
Data from the Indian cohort was collected in 2007 to 2008 in the state of Tamil Nadu, 
through networks caring for people living with HIV. Participants were residing in and around 
the cities Chennai and Vellore [100]. Data from the United States cohort was collected in 
three different states; Iowa [98], South Carolina [98] and Chicago, between 2005 and 2010. 
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3.3.4 Data used for comparison 
3.3.4.1 Men living with HIV in Sweden 1993-1995 
SWED-QUAL mean scores from men who completed the Stigma and quality of life survey 
were compared to earlier published mean scores from a population of men (n=72) living with 
HIV in Sweden [52]. These men completed SWED-QUAL between 1993 and1995 before 
entering a pharmaceutical trial of an HIV vaccine. Mean age was 37 years (SD=9, range =22-
64 years) and mean duration of HIV infection was 4.9 (SD=3.3, range =0.4-10). Route of 
transmission was primarily male to male sex (96%) and 94% of participants were classified 
as White (Ethnic group). Inclusion criteria were CD4 count >200x10
6
 cells/ml, absence of 
current acute disease, drug or alcohol abuse or neurological and psychiatric dysfunction that 
could interfere with participation in the study [52]. 
3.3.4.2 A Swedish general population 1991 
SWED-QUAL mean scores from a Swedish general population were also used for 
comparison. Brorsson et al [53] distributed SWED-QUAL in 1991 to a random stratified 
sample from the Swedish general population (2366 individuals, age 18-83). 
3.4 PARTICIPANTS 
In the Stigma and quality of life survey, 193 individuals returned a questionnaire (44% 
female, 52% born in other countries than Sweden, mean age = 48.8, SD = 11.7, range = 19-
83). Thirty-two participants had completed the questionnaire with assistance from me or 
another member of the research team, 8 participants had completed the questionnaire with 
assistance from a professional translator.  
3.4.1 Paper I 
Data used in paper I were responses to items in the HIV stigma scale from the Stigma and 
quality of life survey. Sociodemographic variables for all participants that returned a 
questionnaire (n=193) are presented in Table 3. For the exploratory factor analysis only 
participants who had completed all items in the HIV stigma scale were included (n=132, 
Table 3). We were concerned that a large proportion of the participants with missing answers 
in the Stigma and quality of life survey would be participants born in other countries than 
Sweden, but there was no statistical difference between the subsample of persons with 
complete answers to the HIV stigma scale and the sample of all persons returning a 
questionnaire (Table 3).  
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Table 3. The stigma and quality of life survey, categorical sociodemographic variables  
   Subsamples in analyses  
 Returned 
questionnaires 
n=193 
EFA/CFA 
 
n=132
a
 
Differences 
between 
n=193 and 
n=132 
PLS-SEM 
 
n=173
 b
 
Differences 
between  
n=193 and 
n=173 
Characteristics n % n % 2(1
) 
p n % 2 (1)  p 
Gender           
Female 85 44 55 42 
0.41 0.522 
74 43 
0.11 0.745  
Male 108 56 77 58 99 57 
Country of birth           
Sweden 93 48 64 49 
0.04 0.845 
84 49 
0.02 0.884 
Other country 100 52 67 51 89 51 
Non-adherent to ART 18 9 17 13 2.43 0.119 16 9 0.01 0.909 
CD4 count<200x10
6 
cells/ml 
8 4 7 5 0.58 0.445 7 4 <0.01 0.975 
On antiretroviral 
treatment
 c
 
185 96 125 95 0.58 0.445 165 95 0.18 0.675 
     2(3
) 
p   2(3) p 
Education           
Elementary School 35 18 24 18 
0.35 0.951 
32 19 
0.61 0.895 
High 
School/Secondary 
School 
70 36 50 38 66 38 
College or 
University degree 
72 38 47 36 63 36 
Ot er/Unknown 16 8 11 8 12 7 
Route of Transmission
 d
           
Heterosexual  117 61 71 54 
3.39 0.335 
99 57 
3.39 0.697 
Homo/bisexual 52 27 44 33 51 30 
Intravenous drug 
use 
13 7 9 7 12 7 
Other/unknown 11 5 8 6 11 6 
a
Participants with complete answers to all items in the HIV stigma scale 
b
Participants with enough items completed to be included in PLS-SEM 
c
Persons not on treatment was not due to non-adherence. Treatment not initiated because of high CD4 count. 
d
Route of transmission as classified in InfCare HIV 
 
3.4.2 Paper II 
The results from the exploratory factor analysis from paper I with 132 participants were also 
used in Paper II. In the partial credit models we used a subsample of participants in the 
Stigma and quality of life survey that had answered all items in a subscale, (n= 157 for 
Personalized stigma, n=168 for Disclosure concerns, n=159 for Concerns about public 
attitudes and n=180 for negative self-image. To evaluate the psychometric properties of the 
12-item version of the HIV stigma scale we retrieved item-level data from the study Living 
with HIV in Sweden [83]. Eight hundred eighty participants out of 1096 had completed all 
items in the HIV stigma scale. We found no statistical difference regarding gender between 
those who had completed all items in the HIV stigma scale and the total sample (26% female 
vs expected 29%, 2(1)= 3.79, p=0.052). 
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3.4.3 Paper III 
Participants in Paper III were people living with HIV in Sweden, South India and the United 
States. The Swedish cohort was the subsample used in the partial credit models in paper II. 
The Indian cohort consisted of people living with HIV (50% female) in the state of Tamil 
Nadu who completed the 40 items in the HIV stigma scale in 2007-2008. 150 participants 
were living in and around the city Chennai (urban area) and 100 were living in Vellore 
(semirural area) [100]. The US cohort consisted of people living with HIV (34 % female) 
who had completed the 40 items in the HIV stigma scale at different time points between 
2005 and 2010. At the time of data collection the US participants lived in South Carolina 
(n=210), Iowa (n=331) and Chicago (n=62) [98, 99]. 
3.4.4 Paper IV 
The participants in Paper IV were drawn from the Stigma and quality of life survey, (the 
same cohort as for Paper I-III). After calculating subscale scores for SWED-QUAL and the 
HIV stigma scale (with missing values imputed for the HIV stigma scale as earlier described) 
participants with missing data on variable level were excluded, leaving 173 participants for 
analyses. We found no statistical difference regarding characteristics between the subsample 
of 173 participants compared to the 193 who completed a questionnaire (Table 3).  
3.4.5 Paper V 
Fifteen persons who were living with HIV and who we knew were durably virally suppressed 
were interviewed. They were born in the different countries Eritrea, Uganda, Kenya, Gambia, 
Thailand, Philippines, Germany and Sweden, but they all had Swedish residency. 
Sociodemographic information about participants on a group level is presented in Table 4. 
Table 4. Participants’ characteristics 
  n=15 
Gender Women 8 
 Men 7 
Country of birth Sweden 6 
 Other country 9 
Age 30-39 1 
 40-49 6 
 50-59 6 
 >60 2 
HIV diagnosis before or after 1996* Before 1996 4 
 After 1996 11 
*When combined antiretroviral treatment was introduced  
 
3.5 STATISTICAL ANALYSIS 
3.5.1 Psychometric properties of the HIV stigma scale in a Swedish context 
(Paper I-III) 
Psychometric properties of the HIV stigma scale was examined in Paper I-III, with a focus on 
validity, which refers to the extent that an instrument measure what it is intended to measure 
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[102]. Paper I-III therefore gives information regarding to what extent it is reasonable to 
believe that the HIV stigma scale assess the experience of HIV-related stigma among people 
living with HIV in Sweden. A schematic overview over analyses performed within each 
paper with data sources used is presented in Table 5. 
Table 5.Psychometric analyses performed within my doctoral project, sorted by data source 
used and with indication of paper where the analyses are published. 
 Data source 
 The HIV stigma 
survey 
Living with 
HIV in 
Sweden 
American and 
Indian cohort 
Content validity    
Data quality, missing values    
Differential item functioning Paper III  Paper III 
Criterion validity    
Convergent validity Paper I   
Construct validity    
Exploratory factor analysis Paper I Paper II Paper III 
Confirmatory factor analysis  Paper II Paper III 
Distribution of scores within subscales Paper I   
Corrected item-total correlation coefficients Paper I Paper II  
IRT evaluation of model fit Paper II   
Floor and ceiling effects Paper I Paper II  
Evaluation of Likert scale Paper I   
Reliability (Internal consistency)    
Cronbach’s alpha Paper I Paper II  
 
3.5.2 The difference between classical and modern test theory 
The HIV stigma scale was originally developed as a factor model with four latent variables 
intended to measure four different aspects of HIV-related stigma; the four subscales are 
treated as summated scales.  Factor models and summated scores belong to classical test 
theory. In this thesis we have also used modern test theory, where a basic assumption is that 
items in a scale may vary in “difficulty” [102] [103].  With the subscale Disclosure concerns 
as example, there would be some items that even those with little Disclosure concerns would 
agree with and some items that only those with much Disclosure concerns would agree with.  
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3.5.3 Paper I 
In Paper I we used classical test theory to evaluate content validity, criterion validity, 
construct validity and internal consistency of the HIV stigma scale in a Swedish context. 
3.5.3.1 Content validity 
Content validity was assessed to see whether items in the HIV stigma scale were sensible and 
reflected the experience of HIV-related stigma for people living with HIV in Sweden at the 
time of data collection for the HIV stigma survey [102]. We examined the rate of participants 
that had missing answers to items in the instrument and if more than 5% of participants had 
not completed an item we examined the content of that item further [104]. We also calculated 
floor and ceiling effects on a subscale level. If more than 15% of participants had maximum 
or minimum score on a subscale it could be suspected that the scale did not measure the entire 
range of the intended aspect of HIV-related stigma [105]. 
3.5.3.2 Convergent validity 
We also assessed convergent validity, which concerns if an instrument can be empirically 
associated with external criteria [102]. We hypothesized that the measures of HIV-related 
stigma in the HIV stigma scale would be related to the SWED-QUAL scales Emotional 
wellbeing, with persons who had reported more experiences of HIV-related stigma reporting 
worse emotional well-being. Thus, we examined Spearman’s rank correlations between HIV 
stigma scale scores and scores from the SWED-QUAL scales Emotional wellbeing: positive 
effect and Emotional wellbeing: negative effect and expected all correlations to be negative, 
since lower scores indicate worse health-related quality of life for all SWED-QUAL scales 
[53].  
3.5.3.3 Construct validity 
Construct validity concerns whether instruments measure the construct that it was intended to 
measure [102]. The HIV stigma scale was originally developed as a factor model using 
traditional psychometric theory and Berger et al. found that the items in the instrument related 
to four latent variables (sub scales) [44]. When testing the construct validity of the HIV 
stigma scale in a Swedish context therefore consisted in testing whether the four factor 
structure was confirmed also in a Swedish context. Construct validation primarily concerns 
dimensionality (i.e. do all items in a subscale relate to a single dimension), homogeneity (do 
all items in a subscale contribute equally to the subscale) and overlap between subscales 
[102]. 
To evaluate construct validity we replicated the factor analysis performed in the development 
of the original scale (alpha factoring, oblimin rotation) using item-level data from “the HIV 
stigma survey” to compare the psychometric properties of the instrument in a Swedish 
context. We used the Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy (KMO) 
(expected to exceed 0.8) and Bartlett’s test of sphericity (expected to be significant) [106] to 
evaluate if the data was suitable for a factor analysis. 
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In contrast to how Berger et al [44] handled the cross loading items, we decided to assign 
each item to one single subscale. If items cross loaded we assigned that item to the subscale 
that it had a higher loading with. When items had been assigned to subscales we calculated 
corrected item-total correlations, assessing how each item was correlated to the intended 
subscale to assess homogeneity. Corrected item-total correlations were considered acceptable 
if exceeding 0.4 and were also expected to have a variation in range [107].  
3.5.3.4 Internal consistency 
We calculated Cronbach’s alpha for all subscales to assess internal consistency, and expected 
figures of > 0.7 if all items were adequately correlated to each other within a subscale.  
3.5.4 Paper II 
Paper II describes how we developed and evaluated a 12-item short version of the HIV 
stigma scale that was used to measure HIV-related stigma in the study Living with HIV in 
Sweden [83]. In the process of item selection we kept items with better psychometric 
properties and excluded items that functioned less well. Since we also wanted to preserve 
content validity we assessed which aspects of stigma that each of the subscales was intended 
to cover and tried to select a combination of item that covered as many aspects of stigma as 
possible. 
3.5.4.1 Item reduction 
The exploratory factor analysis from Paper I was used to assess which items that had lower 
loadings and which items that had high loadings on several subscales (i.e. cross loading 
items). Cross loading items or items that had low loadings to all subscales were not 
considered for the short version. We also used modern test theory (item response theory), 
where it is assumed that items have different “difficulty” level. We calculated partial credit 
models for all subscales where the items were hypothesized to represent more or less severe 
levels of the measure stigma aspect. Items that showed misfit towards the model (Mean 
square values>1.2) were not considered for the short version. We discussed the remaining 
items in the research group and chose three high loading items per subscale that we thought 
represented the different aspects of stigma proposed by Berger et al [44] that the instrument 
should cover.   
3.5.4.2 Evaluation of the 12-item version of the HIV stigma scale 
The 12-item version of the HIV stigma scale was used in the study Living with HIV in 
Sweden and we used item-level data from that study to evaluate the psychometric properties 
of the abbreviated instrument. The 880 participants that had completed all 12 items in the 
HIV stigma scale were randomly divided into two samples of equal size. Item-level data from 
the first sample was analyzed in exploratory factor analysis (alpha factoring, oblimin 
rotation). We then specified a model with the 12 items loading to the intended subscales, 
without cross loadings, and used the second sample to perform a confirmatory factor analysis 
with maximum likelihood. Goodness of fit of the model to the data was evaluated with 2-
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testing (expected to be non-significant), RMSEA (expected to be below 0.5), and CFI and 
TLI (expected to exceed 0.9).  
To compare psychometric properties between the 39-item version and the 12-item version of 
the HIV stigma scale we calculated corrected item-total correlations, Cronbach’s alpha and 
floor and ceiling effects for the subscales in the12-item version of the instrument. 
3.5.5 Paper III 
In Paper III we used data from the South Indian and the US cohort and compared 
psychometric properties between those cohorts and our Swedish cohort.  Participants in all 
cohorts had answered the 40-item version of the HIV stigma scale, but based on our 
knowledge that the 40-item version of the HIV stigma scale had extensive cross loading in an 
American context we chose to only use 32 items included in an abbreviated version of the 
instrument, developed with an intention to remove cross loading items [108].  
3.5.5.1 Dimensionality 
We analyzed dimensionality of the subscales and assumed that the subscales separately 
would function as unidimensional constructs. We therefore specified factor models where all 
items in a subscale loaded onto one single factor and assessed model fit for subscales 
separately, and repeated this series of analyses for each cohort. In analysis we accounted for 
the ordinal nature of the data and fitted the models using weighted least squares means and 
variance (WLSMV) [109].  We also assessed dimensionality using the Empirical Kaiser 
Criterion [110]. 
3.5.5.2 Differential item functioning 
We then examined if items in the 32-items version of the HIV stigma scale showed signs of 
differential item functioning (DIF) between the Swedish, South Indian and US cohorts. We 
also assessed DIF between men and women across all cohorts and replicated a DIF-analysis 
performed by Rao et al [98] where DIF was assessed between Black, non-Hispanic and 
White, non-Hispanic persons living with HIV. We used a combined ordinal logistic 
regression –IRT approach, as employed in the Lordif package [111] in R statistics. The 
logistic regression were performed in three steps were the first step consisted of a graded 
response model, with the probability for item responses calculated as a function of 
participants level of perceived stigma. In the second step group (i.e. cohort) was added as 
independent variable and in the third step an interaction term of group and latent trait level 
combined was added. Differences in pseudo R square values (nagelquerke) between step one 
and two was used to assess uniform DIF, with a constant effect for different levels of stigma. 
Differences in pseudo R square values between step two and three were used to assess non-
uniform DIF, with an effect that differed depending on levels of stigma. Thresholds for when 
items should be flagged for DIF were based on Monte Carlo simulations of DIF-free samples. 
Impact of detected DIF on subscale scores was evaluated through scatter plots of the 
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difference between unadjusted IRT scores (with DIF) and adjusted IRT scores (adjusted for 
DIF). Differences exceeding 0.2 were considered to be salient [112]. 
3.5.6 Paper IV 
3.5.6.1 Descriptive statistics for the HIV stigma scale 
The Swedish version of the HIV stigma scale was used to measure different aspects of HIV-
related stigma; Personalized stigma, Disclosure concerns, Concerns about public attitudes and 
Negative self-image. We calculated subscale scores for the four subscales in the HIV stigma 
scale by summarizing item scores across subscales. Missing values were imputed using 
multiple imputations if respondents had completed at least 50 % of items in a subscale. Since 
the subscales consist of 7, 8, 8 and16 items respectively the subscale scores are not directly 
comparable across subscales. To generate descriptive statistics that was comparable across 
subscales we dichotomized the subscale scores into two categories; lower stigma and higher 
stigma. The cutoff-value was set to be half of the maximum range and the subscale scores 
were thus categorized as presented in table 6.   
Table 6. Possible range for subscale scores in the HIV stigma scale and cutoff values for 
dichotomized categories. 
HIV stigma Subscale Possible range 
subscale score 
Dichotomized categories (lower 
stigma/higher stigma) 
Personalized stigma 16-64 16-40/41-64 
Disclosure concerns 8-32 8-20/21-32 
Concerns about public attitudes 7-28 7-17/18-28 
Negative self-image 8-32 8-20/21-32 
 
3.5.6.2 Comparison of SWED-QUAL scores 
Scores for the 11 SWED-QUAL scales were transformed into scores from 0-100, with higher 
scores indicating better health-related quality of life for all scales. Since we were interested in 
knowing whether the health-related quality of life had improved with the use of modern 
antiretroviral treatment we excluded participants that was classified as non-adherent. SWED-
QUAL scores from an age-adjusted subsample of men (age >64 and participants classified as 
non-adherent excluded) that completed the Stigma and quality of life survey was compared to 
the mean scores that Eriksson et al [52] reported for men living with HIV, measured 1993-
1995. SWED-QUAL scores from a subsample of the Stigma and quality of life survey 
(participants classified as non-adherent excluded) were also compared to a Swedish general 
population, collected and published by Brorsson et al [53]. Two-tailed, one sample t-tests was 
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used for comparison since we did not have access to individual level data from the 
comparison groups. Differences were regarded significant at p-values below 0.05. 
3.5.6.3 Empirical test of the HIV stigma framework 
The HIV stigma framework [41, 42] is a theoretical model based on research on relations 
between HIV-related stigma and health-related quality of life and behavior. In the HIV 
stigma framework individual level stigma mechanisms are hypothesized to be differently 
related to health-related quality of life and behavior. Our hypothesis was that the part of the 
framework that regards people living with HIV would be valid also in a Swedish context, 
with a high proportion of people who are virally suppressed. To test this hypothesis we 
specified a path model, based on the HIV stigma framework. Since we did not have access to 
the exact same measures as Earnshaw et al [42] used in their empirical test of the framework 
we operationalized the concepts in the HIV stigma framework as shown in Table 7. We were 
interested in if the paths in the model differed depending on covariates. We therefor added 
age and a combined measure of gender and country of birth as potential covariates in the 
model, hypothesized to be correlated to measures of stigma and have a direct effect on 
measures of health and wellbeing. The path model was tested using partial least squares 
structural equation modeling (PLS-SEM) in smartPLS 3 [113]; significances were assessed 
through bootstrapping.  
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Table 7. Concepts in the HIV stigma framework and corresponding measures used in the 
present study 
Concept in the 
HIV stigma 
framework 
Description of concept as 
described by Earnshaw et al 
Measure used in 
PLS-SEM (n items) 
Brief description of 
measure used in the 
present study 
Enacted stigma “The degree to which PLWHA 
believe they have actually 
experienced prejudice and 
discrimination from others in their 
community” [41] 
Personalized stigma
a
 
(16) 
Perceived consequences 
of other people knowing 
about one’s HIV  
Anticipated stigma “The degree to which PLWHA 
expect that they will experience 
prejudice and discrimination from 
others in the future” [41] 
Disclosure concerns
a
 
(8) 
Concerns about 
disclosing one’s HIV 
status to others  
Concerns with public 
attitudes
a  
(7) 
Concerns about other 
people’s opinion about 
HIV  
Internalized stigma 
“The degree to which PLWHA 
endorse the negative beliefs and 
feelings associated with HIV/AIDS 
about themselves” [41] 
Negative self-image
a
 
(8) 
Feeling of being 
unclean, not as good as 
others because of HIV  
Physical health and 
wellbeing 
 Physical functioning 
b  
(7) 
To what extent one’s 
health interferes with 
ability to perform 
physical activities  
Behavioral health 
and wellbeing 
 Antiretroviral 
adherence 
Non-adherence as 
defined by one VL>150 
copies/ml or two or 
more consecutive VL 
>50 copies/ml within 
the last two years of the 
condition with treatment 
ongoing at least six 
months prior to the 
evaluation period 
Affective health and 
wellbeing 
 Emotional wellbeing: 
negative effect
b 
(6)
 
Negative feelings during 
the last week  
Emotional wellbeing: 
positive effect
b 
(6)
 
 
Positive feelings during 
the last week  
a
Subscales of the HIV stigma scale [44]
                                                                                                                                                                                                                                                                                                                         
b
Subscales of the SWED-QUAL [53]
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3.6 QUALITATIVE ANALYSES  
3.6.1 Paper V  
The interviews were analyzed in a content analysis with framework approach [114, 115] with 
the HIV stigma mechanisms as predetermined codes. The interviews were transcribed by a 
professional transcriber and I and the second author of the paper listened to all interviews and 
read the transcripts to get familiar with the content. We wrote down ideas and thoughts that 
emerged and discussed the content in the interviews within the research team. Based on our 
notes we made a preliminary code index that we used when coding the interviews. Me and 
the second author coded interviews in parallel and discussed the coding index at weekly 
meetings. The coding index were changed during this time until we had coded all interviews 
and agreed on coding.  
 
4 ETHICAL CONSIDERATIONS 
All procedures described within this thesis were performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments [116].  
4.1 ETHICAL PERMITS 
When I started my doctoral project, Lars Eriksson was already involved in a project studying 
stigma and health-related quality of life among persons with resistant bacteria (MRSA); 
approved by the Regional Ethical Review Board in Stockholm, Sweden (2008/1794-31). 
Ethical approval for data collection with persons living with HIV in Sweden (the stigma and 
quality of life cohort) was approved as amendments to the study about MRSA (amendment 
2013/335-32 for the survey and data retrieved from InfCare HIV and amendment 2017/222-
32/1 for the individual interviews). 
The study Living with HIV in Sweden was approved by the Regional Ethical Review Board 
in Stockholm, Sweden (3013/4:8). 
Ethical permit for data collection in South India was granted by the Institutional Review 
Boards of the Christian Medical College, Vellore , ref IRB Min No 6946, and the University 
of Washington, Application no 37317 C. Ethical permits for data collection in Chicago, US, 
was granted by Northwestern University Institutional review board, IRB Project Number: 
STU00009286 with attached IRB authorization agreement. Ethical permit for data collection 
in Iowa and South Carolina, US, was granted by Northwestern University Institutional review 
board, IRB #2078-001, but the documentation has been recycled since more than seven years 
have passed since data collection (following US regulations). When Deepa Rao and Lisa 
Manhart shared their data with me, ethical permit was not needed since identifiers were 
removed from the data. 
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4.2 INFORMED CONSENT  
Written information about the study was available in Swedish or English (Appendix 2) 
regarding the survey and in Swedish regarding the individual interviews. Potential 
participants were informed that participation was completely voluntary and that their care 
would not be affected if they declined to participate. When possible a professional translator 
translated the information for potential survey participants that did not understand Swedish or 
English.  
4.3 PRIVACY AND CONFIDENTIALITY 
All collected data was treated with confidentiality and data from the survey was only 
presented on a group level. I and other persons working with data collections had access to 
code numbers connected to InfCare HIV for potential participants during data collection. This 
code number could be used to access information about individual participants through 
InfCare HIV, but only by persons with a right to access the medical records. When data was 
entered into database, the InfCare HIV number was replaced by a new anonymous code. 
Some persons were concerned about confidentiality and did not want to sign the consent form 
with their name.   
4.4 RISK, BURDENS AND BENEFITS 
We identified a potential risk that participants would react negatively when answering the 
questionnaire or participating in interviews. If someone had been in need of support after 
participation, that person would have been referred to a social counselor at the clinic.  
5 RESULTS 
5.1 PAPER I  
In this paper we used classical test theory to evaluate content validity, convergent validity, 
construct validity and internal consistency of the HIV stigma scale in a Swedish context. 
Results from the psychometric evaluations are presented in Table 8 (subscale level) and Table 
9 (item level). 
5.1.1 Content validity 
The percentage of missing values exceeded 5% for 18 items (Table 9), of which 13 were 
items that assume that at least some persons, other than the participant and health 
professionals at the HIV clinic, knew about the participants HIV. Some participants had also 
written in the margin of these items that “nobody knows”. The highest rate (10.8%) of 
missing items was seen for item 5 (People with HIV lose their jobs when their employer find 
out) and some participants had written in the margin: “does this happen in Sweden?” Floor 
and ceiling effects were below 15% for all subscales (Table 8). 
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5.1.2 Convergent validity 
As hypothesized we found all subscales in the HIV stigma scale to be negatively correlated to 
measures of Emotional wellbeing (Table 8). Effect sizes of correlation coefficients were 
moderate for Personalized stigma, Concerns about public attitudes and Negative self-image 
but small for Disclosure concerns. 
5.1.3 Construct validity 
The data was suitable for factor analyses with a KMO of 0.910 and a significant Bartlett’s test 
of sphericity. Parallel analysis indicated a four factor solution with loading strengths for the 
four factor solution as presented in Table 9. Item 11 (It is easier to avoid new friendship than 
worry about telling someone) had no loadings exceeding 0.32 and we therefore decided to 
remove it from the instrument.  
Figure 7. shows a matrix with correlations between items in the HIV stigma scale (darker red 
indicate a higher correlation coefficient). The items in the matrix are ordered after how we 
assigned items to subscales in the Swedish version of the HIV stigma scale.  With an ideal 
factor structure items would be more strongly correlated within subscales and less correlated 
across subscales. As seen in Figure 7 this seems to be the case for the subscale Personalized 
stigma, but less clearly for other subscales.  
The weighted summations of the item scores on each subscale (i.e. loading strength) are 
shown to the right of the correlation matrix in Figure 7. Although the correlation matrix 
showed overlap between latent variables in general, the factor analysis generated a somewhat 
clear four-factor structure. When Berger et al [44] developed the instrument all items but two 
had overlap between latent variables (loadings >0.32 for more than one latent variable). The 
Swedish version of the HIV stigma scale had considerably less overlap than when Berger et 
al analyzed the original version. 
Corrected item-total correlations all exceeded 0.4 (Table 9) and also had a range within 
subscale, which indicated that the items measured a broadness of the aspect of stigma 
intended to measure.  
5.1.4 Internal consistency 
Cronbach’s alpha for the subscales ranged from 0.87 to 0.96 (Table 3). 
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Figure 7. Correlations between items in the HIV stigma scale from Paper I. Darker red indicates higher correlation and black  
squares frame the items that were assigned to each subscale. Colored bars to the right are loading strengths from the factor analysis.
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5.2  PAPER II 
In paper II we described the development of an abbreviated version of the HIV stigma scale 
and tested the psychometric properties of the 12-item instrument. 
5.2.1 Item reduction 
Items for the 12-item version of the HIV stigma scale were selected from the 40-item version 
in a process of item reduction. As already reported in Paper I, item 11 had no loadings 
exceeding 0.32 and five items had loadings exceeding 0.32 on two subscales (Table 9). These 
items were not considered for the 12-item version of the HIV stigma scale. In addition to the 
classical psychometric analyses performed we also calculated partial credit models and 
assessed measures of item misfit. Items with mean square values exceeding 1.2 (Table 9) 
were not considered for the 12-item version of the instrument. From the remaining items we 
chose the items marked with grey background in Table 4 for the abbreviated version of the 
HIV stigma scale.  
5.2.2 Evaluation of the 12-item version of the HIV stigma scale 
Eigenvalues for the four factors were all above 1 and the 12-item version did not have cross 
loadings (Table 9). The confirmatory factor analysis showed standardized effects >0.7 for 
items on intended scales. Alternative fit measures indicated acceptable fit (CFI: 0.963, TLI: 
0.950, RMSEA: 0.071. The 2 test was however statistically significant (2 =154.2, DF=48, 
p<0.0001) which indicated the model was inconsistent with the data.  
The 12-item version had floor effects for the subscales Personalized stigma and Negative 
self-image. Ceiling effects in the 12-item version of the subscale were seen in the scale 
Disclosure concerns (Table 8). Cronbach’s alpha was above 0.7 for all subscale, also in in the 
abbreviated version of the instrument (Table 8). 
5.3 PAPER III 
In paper III we compared psychometric properties for the HIV stigma scale between the 
Swedish Stigma and quality of life survey cohort and cohorts of people living with HIV in 
South India and the US. 
5.3.1 Dimensionality 
The subscales were treated as unidimensional constructs and the dimensionality was assessed 
with both confirmatory and exploratory methods. The confirmatory factor analyses supported 
the unidimensional models for Disclosure concerns and Concerns about public attitudes for 
the Indian Cohort and for Negative self-image for the Swedish cohort. For other subscales a 
significant 2 test indicated that the subscales might not be unidimensional in all contexts 
(Paper III, Table 2). According to the Empirical Kaiser Criterion 2 factors would be adequate 
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to retain from Disclosure concerns and Negative self-image regarding the South Indian 
cohort, and from Disclosure concerns regarding the Swedish cohort (Table 8).  
5.3.2 Differential item functioning 
Nine items were flagged for DIF between the Swedish, South Indian and US cohort (Table 9, 
one item in Personalized stigma, five items in Disclosure concerns, one item in Concerns 
about public attitudes and two items in Negative self-image). The DIF had a negligible 
impact on individual IRT scores for Personalized stigma, Concerns about public attitudes and 
Negative self-image. However, the DIF for Disclosure concerns did have a salient impact on 
individual IRT scores in the Swedish and South Indian cohort (Paper III, Figure 1). No salient 
DIF was found regarding gender. 
 
Figure 8. Item response functions for the items that were flagged for DIF within the subscale Disclosure 
concerns.  
 
Item response functions for items within the subscale Disclosure concerns that were flagged 
for DIF are shown in Figure 8. These graphs show probabilities for participants with different 
level of Disclosure concerns to endorse the four response alternatives. If the items were 
without DIF the black, red and green lines would be identic. For item 1, 17, 21 and 37 the 
lines were, for some cohorts, flatter than expected, which may indicate a misfit towards data 
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in the item response theory model (i.e. the item did not function properly). Item 6 (I work 
hard to keep my HIV a secret) on the other hand, had item response functions that, by 
appearance, seemed to function well for countries separately, but functioned differently for 
separate countries (i.e. differential item functioning).  
5.4 PSYCHOMETRIC PROPERTIES FOR THE HIV STIGMA SCALE (PAPER I-
III) 
Table 8 and 9 present combined results regarding psychometric properties for the HIV stigma 
scale from Paper I-III. The subscale level results (Table 8) indicate that the psychometric 
properties for Disclosure concerns may questionable, with low correlations to Emotional 
wellbeing and results indicating multidimensionality. Some items measuring Disclosure 
concerns were also flagged for differential item functioning between the Swedish and South 
Indian cohort (Table 9).  
On an item-level (Table 9) it was noteworthy that items measuring Personalized stigma in 
general had a rate of missing values exceeding 5%. Seven items in the subscale Personalized 
stigma also showed misfit towards the graded response (IRT) model. Results indicated that 
the two items that are positive statements in the HIV stigma scale (item 8 and item 21) were 
not functioning well. They were both flagged for differential item functioning, had poor fit to 
the graded response model and were only moderately correlated to their respective subscale. 
The same pattern, with low item-total correlation, misfit towards the IRT model and sings of 
differential item functioning, was, however, also seen for item 1 and 5, which were negative 
statements 
 
Table 8. Subscale-level results from the psychometric evaluations of the HIV stigma scale. 
Subscale Correlations to 
emotional wellbeing 
(SWED-QUAL) 
 Floor/ 
Ceiling 
effect (%) 
Dimensionality
 a
 
(Sweden/South India/ 
US) 
 Positive
  
effect 
Negative
  
effect 
   
 39-item version 
(12-item version) 
32-item version 
Personalized stigma -0.30* -0.40* 0.96 
(0.88) 
5/2 
(28/6) 
1/1/1 
Disclosure concerns -0.24* -0.21* 0.87 
(0.84) 
1/9 
(6/22) 
2/2/1 
Concerns about 
public attitudes 
-0.29* -0.39* 0.88 
0.81 
2/3 
(9/9) 
1/1/1 
Negative self-image -0.43* -0.49* 0.88 
(0.80) 
7/2 
(24/5) 
1/2/1 
a
 Numbers of factor proposed to retain according to Empirical Kaiser Criterion 
*p<0.01 
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Table 9. Item-level results from the psychometric evaluations of the HIV stigma scale 
Items (Full description in Appendix 1) Item-total 
correlations 
missing 
values% 
Loading strengths from EFA
a
 Outfit 
Msqr 
Infit 
Msqr 
Items flagged for 
DIF
c
  
   1 2 3 4  Uniform Non-
uniform 
Personalized stigma -item version (12-item version) -item version
39 People seem afraid of me … 0.88 7.7 0.866       0.49 0.51 - - 
29 People I care about stopped calling…b 0.81 5.2 0.864 
(0.978) 
      0.59 0.66 - - 
38 People who know …tend to ignore my good points 0.85 6.2 0.833       0.53 0.56 0.0115 - 
28 Some people avoid touching me…b 0.79 5.2 0.824 
(0.862) 
      0.65 0.75 - - 
35 I have stopped socializing with some people… 0.81 5.6 0.776       0.64 0.70 - - 
36 I have lost friends…b 0.79 7.2 0.770 
(0.614) 
      0.75 0.87 - - 
33 People have physically backed away from me... 0.82 7.7 0.726       0.73 0.74 - - 
24 I have been hurt by how some people react… 0.67 5.6 0.721       1.34 1.27 - - 
32 People don’t want me around their children… 0.74 5.6 0.714       0.98 1.01 - - 
30 People have told me that getting HIV is what I deserve… 0.65 4.6 0.700       1.16 1.38 - - 
27 As a rule, telling others… has been a mistake 0.68 5.6 0.677  0.344     1.16 1.21 - - 
31 Some people close to me are afraid others will reject them.. 0.73 6.2 0.671       1.09 1.10 - - 
26 I regret having told some people… 0.63 4.6 0.642 0.327      1.68 1.51 - - 
34 Some people act as though it’s my fault… 0.79 5.2 0.638       1.21 0.88 - - 
40 When people learn… they look for flaws in your character 0.76 7.7 0.627       1.26 0.98 - - 
18 Some people who know… have grown more distant 0.63 5.6 0.604       2.00 1.46 - - 
Disclosure concerns           
6 I work hard to keep my HIV a secret 
b
 0.69 1.5   0.751 
(-0.870) 
    0.58 0.63 0.0517 - 
17 I am very careful who I tell I have HIV 
b
 0.70 2.1   0.746 
(-0.748) 
    0.64 0.69 0.0219 0.0181 
1 In many areas of my life, no one knows… 0.53 2.1   0.696     1.56 1.14 0.0293 0.0204 
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21 (Reversed) I never feel the need to hide… 0.51 3.1   0.575 -0.411   1.33 1.29 0.0242 - 
4 Telling someone I have HIV is risky 
b
 0.69 2.6   0.614 
(-0.764) 
    0.87 0.80 - - 
25 I worry that people who know… will tell others 0.68 3.6 0.362 0.542     0.84 0.86 - - 
22 I worry that people may judge me… 0.74 2.1   0.493     0.76 0.73 - - 
37 I have told people close to me to keep… HIV a secret 0.49 6.7   0.402     1.33 1.25 - 0.0191 
Negative self-image           
15 Having HIV makes me feel that I’m a bad person 0.75 2.6     -0.737   0.67 0.73 - - 
7 I feel I am not as good a person as others…b 0.75 2.1     -0.698 
(-0.663) 
  0.74 0.70 - - 
3 People’s attitudes about HIV makes me feel worse…b 0.70 3.1     -0.665 
(-0.758) 
  0.76 0.82 0.0174 - 
8 (Reversed) I never feel ashamed… 0.40 1.0     -0.654   1.36 1.41 0.0502 - 
12 Having HIV makes me feel unclean 0.72 2.6     -0.570   0.78 0.79 - - 
2 I feel guilty because I have HIV
b
 0.66 2.2     -0.532 
(-0.759) 
  1.11 1.02 - - 
23 Having HIV in my body is disgusting… 0.66 2.6    -0.530   0.97 0.99 - - 
13 …I feel set apart and isolated… 0.59 2.6 0.357   -0.484   0.98 0.97 - - 
Concerns about public attitudes           
20 Most people are uncomfortable..
b
 0.79 5.7       -0.769 
(0.604) 
0.55 0.56 - - 
9 People with HIV are treated like outcasts 
b
 0.63 4.6       -0.639 
(0.705) 
1.02 0.94 - - 
14 Most people think that a person with HIV is disgusting 0.69 4.6       -0.613 0.87 0.81 - - 
10 Most people believe that a person who has HIV is dirty 
b
 0.68 4..1       -0.599 
(0.783) 
0.73 0.76 - - 
16 Most people with HIV are rejected when others find out 0.57 6.2       -0.598 1.05 1.08 - - 
5 People with HIV lose their jobs… 0.55 10.8       -0.477 1.24 1.21 0.0188 - 
19 … I worry about people discriminating against me 0.71 2.1       -0.389 0.93 0.84 - - 
 
a 
Loadings below 0.32 not shown.
 
Item 11 was excluded since all loadings were below 0.32.  
b 
Grey background indicate item selected for the 12-item version 
c 
Pseudo R square change (Nagelqerke) 
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5.5 PAPER IV 
5.5.1 HIV-related stigma  
The dichotomized scores for the HIV stigma scale are presented in Figure 8. Disclosure 
concerns was the aspect of stigma that most reported to experience; 64% of participants 
reported Disclosure concerns to a higher extent. 47% also reported Concerns about public 
attitudes to a higher extent. It was more uncommon to have experiences of Personalized 
stigma or to have a negative self-image. 32 % of the participants had experienced 
Personalized stigma to a higher extend, and 31% reported to have a Negative self-image to a 
higher extent. 
 
Figure 8. Percentage of participants in the survey that experienced stigma to a higher extent respectively lower 
extent. 
5.5.2 Health-related quality of life 
Figure 9 shows a comparison of SWED-QUAL scores between a subsample of men from the 
Stigma and quality of life survey cohort (age>64 and participants classified as non-adherent 
excluded) and mean scores from men living with HIV, data collected 1993-1995. Statistical 
differences in mean scores between males (1993-1995) and males (2013) were seen for only 
three of the scales; Physical functioning, Role limitations due to emotional health and Sexual 
function, where scores were significantly lower for males (2013).  
Figure 10 shows a comparison of SWED-QUAL scores between a subsample for the Stigma 
and quality of life survey (participants classified as non-adherent excluded) and a Swedish 
general population, collected and published by Brorsson et al [53] 
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Figure 9. SWED-QUAL mean scores for males living with HIV. Results from 1993-1995 indicated with light 
grey bars and results from the Stigma and quality of life survey 2013 (age>64 and participants classified as non-
adherent excluded) indicated with dark grey bars. Error bars indicate standard deviations. 
*p<0.05 
 
 
Figure 10. SWED-QUAL mean scores. Results from a Swedish general population indicated with light grey bars 
and results from people living with HIV from the Stigma and quality of life survey (participants classified as 
non-adherent excluded) indicated with dark grey bars.  
Error bars indicate standard deviations. 
*p<0.05 
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5.5.3 Relations between stigma and health-related quality of life in a 
Swedish context (Paper IV) 
The result of the path analysis is shown in Figure 11. The subscales in the HIV stigma scale 
were intercorrelated, as expected. Correlations were also found between Physical functioning 
and Emotional wellbeing, both positive and negative effect. Physical functioning and 
Emotional wellbeing was not associated with adherence. Regarding relations between stigma 
and health and wellbeing only three of the hypothesized paths were confirmed. Concerns 
about public attitudes was associated with worse Physical functioning and Negative self-
image was associated with lower Emotional well-being. In contrast to that hypothesized in 
the model Personalized stigma and Disclosure concerns was not related to Physical 
functioning and none of the measures of HIV-related stigma was associated with 
Antiretroviral adherence. Analysis of covariates (not shown in Figure 11.) showed that higher 
scores on the HIV stigma sub scales were associated with younger age. People of younger 
age were also significantly more likely to be non-adherent to antiretroviral treatment. 
Furthermore females, who had migrated to Sweden, had significantly more Concerns about 
public attitudes. Effect sizes of relations including covariates were small. 
 
Figure 11. Results from the PLS-SEM analysis of a path model based on the HIV stigma framework. Boxes to 
the left are measures of HIV-related stigma and boxes to the right measures of health and wellbeing. Estimates 
next to two-way arrows represent correlation coefficients and estimates next to one-way arrows represent 
standardized direct effects. These estimates are calculated with covariates included in the path model, but 
covariates are excluded from this figure to facilitate interpretation. 
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5.6 MAIN FINDINGS PAPER V  
Paper V described the experience of seven men and eight women living with virally 
suppressed HIV in Sweden.  
Although the first period with HIV was described as a crisis, most participants described 
themselves as healthy and HIV as something that did not have a large impact on their lives. 
HIV was generally spoken about as something that the participants lived with but did not 
think about, except occasionally, when they took their medication, or when it came to sexual 
relations. 
In daily life, that is, getting up in the morning and eating breakfast and all that, it doesn’t affect me at 
all. It's just there and we live side by side. I take two pills at breakfast each morning…But that's the 
case for many others who have different diagnoses so that…I don’t think there's anything strange 
about it at all. /Male participant 
The social aspects of living with HIV were, however, described as more or less difficult. 
Some described that HIV today only affected social life when it came to meeting a new 
partner. “It takes a bit of doing before you have told”, a female participant described, “before 
you know how they're going to deal with it. Otherwise it's nothing. Nothing strange”. 
Others described social life as hard and told stories about how they had refrained from all 
forms of close relationships. 
“you just let everything be, that is staying in touch and making friends… You just get rid of 
everything, to get rid of the problem. You give up having a life.”/Male participant 
This male participant, however, also described that he had found a way of living that he was 
satisfied with.  
5.6.1 Stigma mechanisms 
The negative social aspects of living with HIV that we interpreted as part of an individual 
experience of stigma related to HIV was categorized as enacted, anticipated or internalized 
stigma.  
5.6.1.1 Enacted stigma 
Participants told stories about how they had been treated badly by individuals who knew 
about their HIV; for example how they had been left by partners and blocked on social 
media. They also described how laws and regulations restricted their lives. A recurring 
comment in several interviews related to travel restrictions for people living with HIV and 
one participant described being denied access to fertility treatment. The obligation to tell a 
sexual partner about one’s HIV was brought up in negative terms by some participants. 
As the participants HIV status was often not known to others, stigma had not been enacted 
towards them directly. However, they told stories about how other people with HIV or other 
infections had been treated badly, as if those actions had affected themselves. 
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When you work with your colleagues and maybe someone comes in with an infection, maybe 
MRSA or ESBL, and they just say "oh that's disgusting”, “Why do they come here?”, “I don't 
want to go in there”. People… Make me feel sick when I hear that they become… disgusted by 
infections. /Female participant. 
One participant, whose closest community consisted of fellow countrymen and 
who had told no one about his HIV, said that he and his friends often talked about 
those who they knew had HIV; “my friend said to me, he draw the joker, that’s 
how we say it… people talk behind, not in front…” 
5.6.1.2 Anticipated stigma 
Participants commonly described that they anticipated stigma in some specific contexts, but 
not in others. These contexts could be what one participant described as the homosexual 
world, a café where fellow countrymen gathered or the specific situation of disclosing to a 
partner. In these settings the participant described that they anticipated being rejected and 
treated badly if their HIV got disclosed. 
It's a totally different situation in the homosexual world. There you're still labeled. We're so tough. 
We judge everyone really hard, we gay men, terribly hard. It's …It's happened to me and I know 
people whose…conversations are deleted on those mobile apps, you get labeled as sick, in quotes, 
and all that kind of stuff, and it's really tough. It's really hard, so a lot of people are hesitant about 
being open. /Male participant 
Apart from being treated badly by people who knew about their HIV, participants described 
that they anticipated that people who knew would tell others. A male participant described 
that if his HIV got known to one of his fellow countrymen, everybody within the community 
would know within a week; "I can't be here", he said, "I going to move to another country. I 
can't live here…you know everyone will talk about me…so I just can't be comfortable 
here…I'm going to move tomorrow, I can't stay here".  
Participants also described how they anticipated to be defined by their HIV if they were open 
and told others.  
I'm so really torn because...it shouldn't matter…I'm first and foremost (participants name) and I'm 
also a whole lot of other things before I'm HIV, sort of. That's where it gets hard. Then I become 
HIV-(name)...and that's the question, do I want that? The dream is just to be simply (me), that's my 
dream, that you are accepted for who you are and aren't categorized by…which socks you have or 
what job or how much money you make or if you have HIV /Male participant 
Participants also described that they made decisions about how and when they would tell that 
they had HIV in every new encounter. “you sort of have to… come out every time to someone 
new..”. HIV was sometimes described as private and sometimes as something that other 
people were not that interested in hearing about.  
Participant described how they hid their medication or put the pills in a jar for vitamins. One 
participant described that he would wait until he was alone before he took his medicine. “If I 
am together with friends, I won’t take them, I just go home afterwards”.  
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5.6.1.3 Internalized stigma 
Most participants described that their HIV had not affected the way that they looked upon 
themselves. “It's hasn't affected by self-image at all”, a male participant said, “I've never 
gotten into self-hatred or become self-destructive, more the opposite.” 
Some participants, however, described feelings of shame or embarrassment and described 
how they took self-made precautions to protect others. A female participant who worked with 
children described how she worried over transmitting HIV to them: 
 Now that I work with children, I worry so much. Darn, can I infect the kids? Every time I use…gloves. If 
they fall or something. When I clean or wash that sore, I have to have gloves. Not for my sake, it's for her 
sake. If I see blood or anything, I run, lift up the child, and immediately put on gloves. /Female 
participant 
6 DISUSSION 
6.1 SUMMARY OF FINDINGS 
People who were virally suppressed did not think about their HIV much in general, but some 
still experienced social life as difficult. Some had been treated badly because of their HIV and 
they anticipated rejection or labeling if their HIV got known to others. A majority of 
participants had not experienced enacted stigma, but it was common to have concerns about 
when and to whom you would disclose your HIV (64% of participants had disclosure 
concerns to a higher degree). It was also common to have concerns about public attitudes 
regarding HIV (49% had concerns about public attitudes to a higher extend). Although 
Sweden is in the front line regarding treatment, the results in this thesis indicate that the 
health-related quality of life does not seem to improve for people living with HIV in Sweden. 
Associations between stigma and lower health-related quality of life were in general, 
however, not confirmed in the Swedish context. Internalized stigma was found to be 
associated with lower emotional wellbeing and concerns about public attitudes with worse 
physical functioning. HIV-related stigma was in general experienced to a higher extent by 
persons of younger age and women, born in other countries than Sweden had, in general, 
more concerns about public attitudes. Persons who were non-adherent to treatment did not 
report stigma to a higher extent in general.  
6.2 DISCUSSION OF MAIN FINDINGS 
In the following sections I will discuss the main findings in the thesis under the following 
headlines: Conceptualization of HIV-related stigma, Measurement of HIV-related stigma and 
Relationships between HIV-related stigma and health-related quality of life.  
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6.2.1 Conceptualization of HIV-related stigma 
6.2.1.1 Internalized stigma 
In the individual interviews (Paper V) some participants described feelings of shame or 
embarrassment over their HIV. The stories were similar to how Earnshaw et al [42] defined 
internalized stigma (i.e. when people living with HIV endorse negative feelings and believes 
about HIV and applies them to themselves). Internalized stigma, as defined by Earnshaw et al 
[42] was also found to be consistent with the content in the items that constitutes the negative 
self-image subscale in the HIV stigma scale (Paper IV). Although only 29% of participants in 
the Stigma and quality of life survey reported to have a negative self-image to a higher extent, 
negative self-image was found to be associated to lower emotional wellbeing and we 
recognize this aspect of stigma to be important also in the era of efficient treatment.  
6.2.1.2 A mixed experience of enacted and anticipated stigma  
Based on findings in Paper V, I would argue that it may be difficult to always distinguish 
between anticipated stigma (i.e. expectations of discrimination, stereotyping and/or prejudice 
from others in the future [42]) and enacted stigma (i.e. experiences of discrimination, 
stereotyping and/or prejudice [42]). The experience of seeing other people being exposed to 
stigma (e.g. colleagues saying that a person with infection is disgusting) did not only result in 
participants anticipating that they would be exposed to stigma if their HIV got disclosed. 
They also described the event as something that happened to them directly (“it makes me feel 
sick”). 
6.2.1.3 Disclosure 
Disclosure and non-disclosure of one’s HIV was a central topic in the interviews (Paper V) 
and a majority (64%) of participants in the Stigma and quality of life survey reported 
Disclosure concerns to a higher extent (see above). In the interviews participants described 
how they anticipated being rejected or discriminated if their HIV got disclosed and a common 
reason for not disclosing was a fear that HIV would be the prime factor defining them as 
persons. Some participants, however, described other reasons for non-disclosure (e.g. “it 
shouldn’t matter”, “it’s private” or “people are not that interested) and it is of essence to 
recognize that non-disclosure of one’s HIV not always can be explained by fear of negative 
reactions from others. If HIV is a normalized chronic condition, it also becomes less relevant 
to tell people about one’s HIV status. Some participants had the approach that HIV was not a 
secret, but at the same time nothing that they told people about in general. 
According to Goffman [35], a person with a consealable stigmatized identity will with every 
new encounter find her or himself in situations where he and she must decide whether to 
disclose or not, and how. Goffman also described a kind of etiquette of disclosure, as 
disclosure potentially makes other people uncomfortable. A socially accepted way to disclose 
may, according to Goffman, be to wait for a suitable opportunity and then calmly disclose in 
a way that saves present people from embarressment [35].  
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6.2.2 Measurement of HIV-related stigma 
Berger’s HIV stigma scale was used for measurement of experiences of HIV-related stigma 
in paper IV and psychometric properties of the instrument was examined in paper I-III. Both 
a 39-item version was adapted for (Paper I) and a 12-item version developed (Paper II) and 
evaluated in the Swedish context.  
6.2.2.1 Content validity 
The items in the HIV stigma scale was originally generated through a thorough literature 
review of research regarding HIV-related stigma; items were intended to cover all aspects in 
Berger’s conceptual model of perceived stigma in people living with HIV (Figure 5). I found 
the original item generating process performed by Berger et al [44] to be meticulous and 
judged to be in accordance with the protocol as describe by Fayers and Machin [102]. Since 
the Swedish version of the items matched the English version it may be expected that also the 
Swedish version covers Berger’s conceptual model of perceived stigma in people living with 
HIV. The HIV stigma scale does, however, not entirely cover all HIV stigma mechanisms, as 
proposed in the HIV stigma framework [42]. The subscale Negative self-image was found to 
be consistent with the concept of Internalized stigma, and the subscale Personalized stigma 
with the concept Enacted stigma. The subscales Disclosure concerns and Concerns about 
public attitudes could, however, only been seen as proxy measures of the Anticipated stigma 
concept. As anticipated stigma has been defined as when people living with HIV anticipate 
experiencing prejudice and discrimination in the future [42], only one item (number 19.” 
Since learning I have HIV, I worry about people discriminating against me”) reflects that 
aspect directly. However, based on my discussion regarding conceptualization of stigma 
above, I would suggest that the subscales Concerns about public attitudes and Disclosure 
concerns would have better content validity for how people who are virally suppressed 
experience stigma. 
The differential item functioning (DIF) for items in the subscale Disclosure concerns might 
indicate that the concept of Disclosure concerns are not equivalent across different context. 
However, earlier research has shown that multidimensionality in a scale can be mistaken for 
DIF, if the scale is treated as unidimensional in analysis of DIF [129]. Based on the results of 
the psychometric analyses in Paper I-III, I would suggest that the differential item 
functioning, at least partially, can be explained by multidimensionality in the Disclosure 
concerns subscale.  
Five percent of people living with HIV in Sweden had only disclosed their HIV to 
government agencies or health care personnel, according to the study Living with HIV in 
Sweden [83]. This could explain the high rate of missing answers to items in the HIV stigma 
scale that assumed disclosure to some extent and the subscale Personalized stigma may not be 
valid for persons who have not disclosed their HIV to others. High rates of missing answers 
to items in the subscale Personalized stigma has also been noted when the HIV stigma scale 
was used to measure stigma among children and youths living with HIV in Sweden [82, 117]   
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6.2.2.2 Construct validity  
Both the 39-item version and the 12-item version of the HIV stigma scale had acceptable 
construct validity in general in the Swedish context. In fact, the instruments had better 
psychometric properties than the original 40-item HIV stigma scale with less cross loadings 
in the Swedish context. Some items, however, had less satisfactory psychometric properties 
and were therefore excluded from the 12 item version of the instrument. A limitation of the 
12-item version of the instrument, however, was floor and ceiling effects that were not seen 
for the 39-item instrument. 
Item 11 was excluded due to questionable psychometric properties when the Swedish version 
of the HIV stigma scale was presented in Paper I. However, Paper I-III together showed that 
more items were problematic and I would recommend considering if more items should be 
removed in future versions of the instrument (e.g. the reversed items 8. “I never feel ashamed 
of having HIV” and 21. “I never feel the need to hide the fact that I have HIV”).  Items that 
cross load should also be removed (i.e. number 13. “Since learning I have HIV, I feel set 
apart and isolated from the rest of the world”, 25. “I worry that people who know I have HIV 
will tell others”, 26. “I regret having told some people that I have HIV” and 27. “As a rule, 
telling others that I have HIV has been a mistake”) 
6.2.2.3 The subscale Disclosure concerns 
The subscale Disclosure concerns stood out as a subscale with questionable psychometric 
properties. At the same time Disclosure concerns was that subscale that most participants had 
reported to a higher extent. When the HIV stigma scale was used with Swedish children and 
youths, the subscale Disclosure concerns had a Cronbach’s alpha of 0.55 [117]. The internal 
consistency of the subscale Disclosure concerns was also found to be low (Cronbach’s 
alpha=0.62) when the HIV stigma scale was used among people living with HIV in South 
India [100]. I would suggest that the low alpha for Disclosure concerns, detected in earlier 
studies, may be related to the multidimensionality found in Paper III. And as indicated in 
Paper II, Table 1, the subscale actually covers two aspects of Disclosure concerns; (1) 
worrying about own disclosure of one’s HIV, and (2) worrying that others will disclose one’s 
HIV. This was also recognized by Berger et al [44] when the instrument was first presented. 
6.2.2.4 Recommendations for future use of the HIV stigma scale in a Swedish context 
If the HIV stigma scale were to be used in a Swedish context again I would suggest using the 
abbreviated version. However, I recommend adding one item per subscale two prevent floor 
and ceiling effects. For each subscales I would suggest to add a high loading item with good 
psychometric properties according to results presented within this thesis (Table 9). The items 
would then constitute a 16-item scale, which I present in Appendix 3. In this proposed 16-
item version the subscale Disclosure concerns is intended to measure the aspect of keeping 
one’s HIV a secret.  
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6.2.3 Associations between HIV-related stigma ad health-related quality of 
life 
6.2.3.1 Empirical test of the HIV stigma framework 
Our basic hypothesis in this project was that HIV-related stigma would be associated to 
worse health-related quality of life for people living with HIV, also in the era of efficient 
treatment. The hypothesized relations in the HIV stigma framework were, however, not 
confirmed in the Swedish context except for associations between internalized stigma and 
lower emotional wellbeing, and anticipated stigma and lower physical functioning (Paper 
IV).  
Standardized direct effects may be interpreted as effect sizes comparable to Cohens d, were 
values of 0.2–0.49 are interpreted as small, 0.5–0.79 as medium, and > 0.8 as large [130]. The 
effect size was therefore interpreted as low for associations found between anticipated stigma 
and lower physical functioning and between internalized stigma and lower emotional 
wellbeing.    
6.2.3.2 Levels of health-related quality of life for people living with HIV in Sweden 
The health-related quality of life was found to be lower for people living with HIV in Sweden 
than for a Swedish general population, and equally low or lower compared to men living with 
HIV in Sweden 20 years ago (see above). Regarding comparison to the Swedish general 
population it should be noted that the norm data was collected over 25 years ago [53], and I 
have not investigated whether the health-related quality of life for people in Sweden in 
general have changed during those last 25 years. Regarding comparison with men living with 
HIV 1993-1995 the samples were matched regarding age, but the proportion of participants 
being born in Sweden or born in other countries, as well as other variables that may have an 
impact on the health-related quality of life may have differed.  
A main finding in the national study Living with HIV in Sweden was that people living with 
HIV in Sweden generally report high quality of life [83], which stands in contrast to the 
results presented in this thesis. Results that regard specific aspects of health-related quality of 
life are, however, more consistent between the two studies, as approximately 30 % of 
participants in Living with HIV in Sweden reported dissatisfaction with physical health, and 
emotional wellbeing [83]. Further on, findings from the interviews within this thesis indicate 
that also a person who’s HIV have had a large impact on the social life (e.g. the male 
participant who said “you give up having a life”) can have found a way to live a good life.  
6.3 METHODOLOGICAL CONSIDERATIONS  
6.3.1 Regarding data sources  
A limitation with the Stigma and quality of life survey was that the questionnaire was 
distributed at one single hospital. Although the sample of patients listed at the clinic was 
judged representative for people living with HIV regarding gender and immigration status, 
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the majority of participants were likely to live in the same urban area. Repeated measures 
were not performed, thus limiting the study to be strictly cross-sectional.  
The response rate for the Stigma and quality of life survey was 44%, which can be considered 
to be low. However, this should be viewed in regard to the fact that the response rate was 
calculated as the number of participants that completed a questionnaire divided with all 
eligible participants; we chose to have a wide definition of eligible, counting many 
participants as eligible even though we knew that they would have needed assistance to be 
able to complete the questionnaire and therefore were not possible to include because of no 
such assistance available at the time point of data collection.  
 
The offer to complete the questionnaire together with a professional translator showed 
difficult to implement as translators needed to be booked well in advance. It was also time 
consuming to complete the questionnaire with a professional translator and some participants 
feared that a professional translator would be someone from their own community that would 
disclose their HIV status to common acquaintances.  
6.3.1.1 Sample size 
We aimed to include 200 participants in the Stigma and quality of life survey, based on a 
power calculation for detecting differences in SWED-QUAL scores compared to the Swedish 
general population. With an alpha criterion of p<0.05 power was 0.99 to detect a difference 
of 10 score points (SD 30), representing a small effect size of 0.33, on the scale from 0-100 
with a sample of 200. Also with the achieved sample size of 173 individuals included in 
comparison of SWED-QUAL scores the power was 0.99. 
6.3.2 Regarding psychometric analyses (Paper I-III) 
In quality of life research, validity is not a characteristic that a certain instrument can be 
proven to have [102] but can be understood as a constant process where more and more 
evidence is acquired regarding whether the instrument behave in the anticipated manner 
[102]. A strength in this thesis is the thorough examination of validity for the HIV stigma 
scale.  
Validity is only one of several psychometric aspects that are important to assess for 
instruments. Other properties that should be satisfied for a measurement to be clinically 
useful are reliability, repeatability, sensitivity and responsiveness [102]. This thesis did not 
include any repeated measures and my ability to examine reliability, repeatability, sensitivity 
and responsiveness was therefore limited.  
The sample size of 132 participants that completed all items in the HIV stigma scale, was 
considered to be sufficient for the exploratory factor analysis, since factors were over-
determined and communalities ranged from 0.35 to 0.80 [118]. A sample size of 200 had, 
however, given a ratio of 1:5 of items compared to number of participants, which often has 
been suggested as a lower limit for sample size in exploratory factor analyses [106].      
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6.3.3 Regarding statistical analyses of stigma and health-related quality of 
life (Paper IV) 
We chose to analyze the path model with PLS- SEM due to the relatively small sample size 
and variables being on different data level (ordinal, binary). PLS-SEM has been presented as 
a preferable alternative to covariance based SEM (CB-SEM) when sample sizes are small 
[119]. A widely used estimation method for sample size in PLS-SEM is that samples should 
be ten times larger than the maximum amount of paths linked to a latent variable in the model 
[119], which would give a minimum sample size of 80 for analysis of the path model in Paper 
IV. This method has however been questioned since it only works properly when 
standardized effects are large and an inversed square root method has been proposed to be 
more robust [128]. Using the inversed square root method in a retrospective calculation of 
sample size gives that standardized direct effects of 0.19 would be able to detect with a 
sample size of 171. The sample of 173 was therefore considered to be sufficient to detect 
associations of a small effect size (standardized direct effects >0.20).  
Although validity for the HIV stigma scale was examined in Paper I-III, I have not evaluated 
validity for SWED-QUAL within my doctoral project. Sexual function and close relations are 
aspects of health-related quality of life that are highly relevant to assess for people living with 
HIV and SWED-QUAL include scales for measurement of family functioning, partner and 
sexual functioning. It is however, important to understand the limitations of these scales. The 
scale Family functioning asks the participant how satisfied they are with different aspects in 
regard to their family. As family is not defined within the scale I find it difficult to know what 
the participant has answered. The partner scale only applies to persons that have a partner and 
do not function as a measure for those who are single. The scale sexual functioning focus on 
the participants own sexual functioning, in form of one’s own sexual interest, ability to relax 
and enjoy sex and ability to get sexually aroused and orgasm. My concern with these scales 
(family, partner, sexual functioning) regarding measurement of health-related quality of life 
for people living with HIV is that the items might miss aspects of not having a family/partner, 
or having concerns about disclosing HIV-status to potential partners.   
Participants viral load was used as a proxy measure for adherence, and adherence (measured 
through self-reported number of missed doses) have been shown to have excellent 
concordance with viral load [120]. In the interviews (Paper V) participants, who all had viral 
loads <50 copies/ml, however, described how they stored their medication in in jars for 
vitamins or postponed to take their medication until circumstances where they were alone. 
This might indicate that participants in the Stigma and quality of life survey who adjusted 
their treatment to avoid stigma (i.e. not fully adherent to dose timing), also were to be found 
among those classified as adherent. 
As discussed earlier the subscales Disclosure concerns and Concerns about public attitudes 
are not direct measures of anticipated stigma, which might explain why the paths including 
these scales were not confirmed in the Swedish context. When Earnshaw and colleagues [42] 
performed their empirical test of the HIV stigma framework the items measuring enacted and 
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anticipated stigma where adapted from measures of HIV-related stigma developed by Visser 
et al [121], not Berger et al [44]. The items used by Earnshaw and colleagues covered enacted 
or anticipated actions of stigma from family members, social/community workers or health 
care workers [122].  
6.3.4 Regarding qualitative analyses (Paper V) 
Credibility of the analysis was enhanced through peer debriefing [123]; I presented 
preliminary results for research colleagues, not involved in the project, and at a meeting with 
a non-governmental organization for people living with HIV who asked critical questions, 
making us aware of our taken for granted biases. Credibility was further enhanced through 
the use of referential adequacy [123], as we postponed analysis of one interview until the 
analysis was finalized.   
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6.4 CONCLUDING REMARKS 
HIV is still a stigmatized condition, even for persons who are virally suppressed. Although a 
majority of people living with HIV in Sweden have not experienced stigma enacted towards 
them, being aware of a stigma around HIV and seeing others with HIV being subject for 
stigma may also affect persons who have not disclosed.  It is common to have concerns about 
when and to whom you should disclose your HIV. Although Sweden is in the front line 
regarding treatment, the health-related quality of life seems to not improve for people living 
with HIV in Sweden. 
 The HIV stigma scale was, in general, found to be a valid measure of HIV-related 
stigma in Sweden. However, content validity was questionable for measure of 
anticipated stigma, as defined by Earnshaw and Chaudoir [41] and the subscale 
Disclosure concerns was found to have questionable psychometric properties. 
 
 Personalized stigma was found to be consistent with the stigma mechansism enacted 
stigma. Hypothesized associations between enacted stigma and lower physical 
wellbeing was not confirmed. Personalized stigma was reported to a higher extent by 
25% of people living with HIV in the Swedish cohort. 
 
 Disclosure concerns were reported to a higher extent by 69% and Concerns about 
public attitudes was reported to a higher extent by 49% of people living with HIV in 
the Swedish cohort. Although the Disclosure concerns subscale had questionable 
psychometric properties, the individual interviews confirmed that questions about 
disclosure are central to people living with HIV in the era of efficient treatment. 
 
 Negative self-image was found to be consistent with the stigma mechanism 
Internalized stigma and a negative association between internalized stigma and lower 
emotional wellbeing was confirmed. Negative self-image was reported to a higher 
extent by 29% of people living with HIV in the Swedish cohort.  
 
 Hypothesized associations between stigma and adherence to treatment was not 
confirmed in general. Howeever, participants described how they adjusted their 
treatment to keep their HIV a secret.  
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7 FUTURE PERSPECTIVES 
The findings in this thesis gave limited answers to why the health-related quality of life for 
the participants was lower than for a general Swedish population. The Stigma and quality of 
life survey was conducted in 2013 and the interviews were performed in 2017. It is possible 
that some of the participants in the Stigma and quality of life survey had been informed by 
their physician that they were exempted from the obligation to inform potential sex partners 
about their HIV. It is, however, likely that most participants in the Stigma and quality of life 
survey were still obliged to inform their sex partners about their HIV, in accordance with the 
Swedish Law for communicable disease control (SFS 2004:168). In the interviews, many of 
the participants said that they had been exempted from the obligation to disclose and they 
talked about different approaches to disclosure.  
I propose that the changes that have been made in the obligation to disclose one’s HIV to 
others might change the stigma around HIV in Sweden. It could also improve the health-
related quality of life for people living with HIV and it would be interesting to monitor the 
experiences of HIV-related stigma and the health-related quality of life among people living 
with HIV in Sweden over time to track these changes. I would suggest that The Public Health 
Agency performs a similar survey as Living with HIV in Sweden in a near future to capture 
changes over a five year period (before and after changes in the application of the Swedish 
Law for communicable disease control). Important measures from the study Living with HIV 
in Sweden to compare over time would be the overall question of quality of life, the specific 
questions regarding different aspects of life, the question regarding disclosure and the items 
in the HIV stigma scale. Due to the floor and ceiling effects in the 12-item version of the HIV 
stigma scale I would suggest using the proposed 16-item version of the HIV stigma scale in 
Appendix 3 for measurement of HIV-related stigma.  
In this project we have deliberately avoided to use the word stigma in questionnaires and in 
interviews, since it may lack an evident meaning in the Swedish language. However, the 
word stigma is used in the most recent report from The Public Health Agency on the 
application of the Swedish Law for communicable disease control, where the Supreme Court 
precedence from 2004 is regarded as stigmatizing people living with HIV [12]. The word 
stigma is also used by Swedish activists and non-governmental organizations. Although I 
present suggestions for how HIV-related stigma can be conceptualized in the era of efficient 
treatment, I propose that much further work needs to be done regarding conceptualization of 
stigma both in general and specifically in a Swedish context. I suggest that people living with 
HIV in Sweden should be included in the process of defining the word.  
When pre-exposure prophylaxis (PrEP) has been implemented in various countries, PrEP 
users have been identified as a new group that may be exposed to stigma and stigma has been 
identified as a barrier to PrEP [124-126]. PrEP is commonly recommended for people at very 
high risk of infection; a recommendation that in itself can be stigmatizing [131]. Stigma 
related to PrEP may be an important area to explore also in a Swedish context and it may be 
of essence to consider less stigmatizing guidelines when PrEP is implemented (i.e. 
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recommend PrEP for people who want to take responsibility for their sexual health) to avoid 
unnecessary stigmatization.  
Finally, I have many times during this project thought about how it is to grow old with HIV. 
Participants have told me stories about how they control information, that HIV is private and 
that they fear rejection if their HIV status gets known to others. In their stories it has seemed 
relatively unproblematic to hide medication from others and living a life without other people 
knowing about one’s HIV. I have wondered how those stories will evolve when people get 
older and might need care and support from others due to their old age.  
8 CLINICAL IMPLICATIONS 
People who do not get access to HIV testing, treatment and care will inevitably need a lot of 
care (both medical care and nursing interventions), but people who are virally suppressed gets 
prescription for their ART and comes for monitoring of treatment results 2-4 times/year. The 
participants in the interviews, however, described getting more support than just support 
related to treatment from their nurses, physicians and social counselors at the clinic. One 
participant, for example, described how finally, after years of worrying that she would 
transmit HIV to her children, a social counselor drank water from her glass and thus made her 
abruptly realize that she was not contagious.  
According to the nursing theorist Dorothea Orem (as cited by Afaf Ibrahim Meleis [127]), 
patients may be in need of nursing care, not only for sufficient intake of air, water and food, 
or for seeking and securing appropriate medical assistance.  Patients may also need assistance 
in (and here I have focused on areas I consider relevant for people who are virally 
suppressed) maintaining balance between solitude and social interactions, avoiding hazards, 
developing within social groups and accepting oneself to be in a particular state of health. As 
HIV still seems to be a stigmatized disease, patients will need special support regarding social 
life. 
Findings in this thesis imply that younger persons may be more exposed to stigma than older. 
Further on, women born in other countries than Sweden may have more concerns about 
public attitudes. Targeted interventions for women born in other countries than Sweden and 
persons of lower age may therefore be warranted.  
A large proportion of people living with HIV in Sweden have concerns regarding disclosing 
their HIV status to others. Although disclosure concerns was not found to be related to lower 
health and wellbeing, questions about disclosure can be brought up by people living with 
HIV in contact with health care. I have understood throughout this project that it sometimes 
can be complicated to advice patients regarding disclosure. Advice to disclose may have 
devastating consequences for individuals who may be rejected from their community. On the 
other hand, participants have shared experiences in the interviews of being surprised to get 
advised not to disclose. I would suggest that the topic of how to advice patients about 
disclosure /non-disclosure may be valuable to address in an open discussion among 
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caregivers at a clinic. It would also be valuable to include people living with HIV in that 
discussion. 
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11 APPENDIX  
11.1 APPENDIX 1 - THE HIV STIGMA SCALE  
Experiences from living with HIV 
This study asks about some of the social and emotional aspects of having HIV. For most 
of the questions, just circle the letters or numbers that go with your answer. There is no 
right or wrong answers. Feel free to write in comments as you go through the questions.  
This first set of questions asks about some of your experiences, feelings, and opinions as 
to how people with HIV feel and how they are treated. Please do your best to answer 
each question.  
For each item, circle your answer: Strongly disagree (SD), disagree (D), agree (A), or 
strongly agree (SA). 
 
 
 
 
 
 Strongly   
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
1. In many areas of my life, no one 
knows that I have HIV 
SD D A SA 
2. I feel guilty because I have HIV SD D A SA 
3. People’s attitudes about HIV 
make me feel worse about myself 
SD D A SA 
4. Telling someone I have HIV is 
risky 
SD D A SA 
5. People with HIV lose their jobs 
when their employers find out 
SD D A SA 
6. I work hard to keep my HIV a 
secret 
SD D A SA 
7. I feel I am not as good a person as 
others because I have HIV 
SD D A SA 
8.  I never feel ashamed of having 
HIV 
SD D A SA 
9. People with HIV are treated like 
outcasts 
SD D A SA 
  
 71 
 
  Strongly 
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
10. Most people believe that a person 
who has HIV is dirty 
SD D A SA 
11. It is easier to avoid new friendship 
than worry about telling someone 
that I have HIV 
SD D A SA 
12.  Having HIV makes me feel 
unclean 
SD D A SA 
13. Since learning I have HIV, I feel 
set apart and isolated from the rest 
of the world 
SD D A SA 
14.  Most people think that a person 
with HIV is disgusting 
SD D A SA 
15. Having HIV makes me feel like 
I’m a bad person 
SD D A SA 
16.  Most people with HIV are rejected 
when others find out 
SD D A SA 
17. I am very careful who I tell that I 
have HIV 
SD D A SA 
18. Some people who know I have 
HIV have grown more distant 
SD D A SA 
19. Since learning I have HIV, I 
worry about people discriminating 
against me 
SD D A SA 
20. Most people are uncomfortable 
around someone with HIV 
SD D A SA 
21. I never feel the need to hide the 
fact that I have HIV 
SD D A SA 
22. I worry that people may judge me 
when they learn I have HIV 
SD D A SA 
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23. Having HIV in my body is 
disgusting to me 
SD D A SA 
 
Many of the items in this next section assume that you have told other people that you 
have HIV, or that others know. This may not be true for you. If the item refers to 
something that has not actually happened to you, please imagine yourself in that 
situation. Then give your answer ("strongly disagree," "disagree," "agree," "strongly 
agree") based on how you think you would feel or how you think others would react to 
you. 
 
  Strongly 
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
24. I have been hurt by how people 
reacted to learning I have HIV 
SD D A SA 
25. I worry that people who know I 
have HIV will tell others 
SD D A SA 
26. I regret having told some people 
that I have HIV 
SD D A SA 
27. As a rule, telling others that I have 
HIV has been a mistake 
SD D A SA 
28. Some people avoid touching me 
once they know I have HIV 
SD D A SA 
29. People I care about stopped 
calling after learning I have HIV 
SD D A SA 
30. People have told me that getting 
HIV is what I deserve for how I 
lived my life 
SD D A SA 
31.  Some people close to me are 
afraid others will reject them if it 
becomes known that I have HIV 
SD D A SA 
32. People don’t want me around their 
children once they know I have 
HIV 
SD D A SA 
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  Strongly 
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
33. People have physically backed 
away from me when they learn I 
have HIV 
SD D A SA 
34. Some people act as though it’s my 
fault I have HIV 
SD D A SA 
35. I have stopped socializing with 
some people because of their 
reactions to my having HIV 
SD D A SA 
36. I have lost friends by telling them 
I have HIV 
SD D A SA 
37.  I have told people close to me to 
keep the fact that I have HIV a 
secret 
SD D A SA 
38. People who know I have HIV tend 
to ignore my good points 
SD D A SA 
39.  People seem afraid of me once 
they learn I have HIV 
SD D A SA 
40. When people learn you have HIV, 
they look for flaws in your 
character 
SD D A SA 
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11.2 APPENDIX 2 – PATIENT INFORMATION 
   
Living with long-term infections 
 
We want to study the life conditions for people living with long-term infections. The 
goal is to inform policy makers and health care providers about the life conditions of 
people living with long-term infections to provide the best possible care and support. 
 
Information about the study 
The study involves answering questions in a questionnaire. It takes about 30-60 
minutes to answer the questions and you do this before or after your appointment at 
the infection clinic. The questions are about your life, how you perceive your illness 
and how others treat you. One question regards religion. When you have filled in the 
questionnaire you return it in a sealed envelope. If you need assistance you can get 
help to fill in the answers to the questions. Background data about you and your 
illness will be collected from your medical record. 
 
Your participation is completely voluntary and your care will not be affected if you 
decline to participate. Your answers and information from your medical records are 
handled with confidentiality. It's only project members who have access to the 
collected data, which is data without your name. 
 
Responsible for the project 
The project is collaboration between the Department of Infectious Diseases, 
Karolinska University Hospital and Karolinska Institutet. The data protection officer 
is Karolinska Institutet, Mats Gustafsson. 
 
Questions about the study can be answered by your regular doctor or any signed. 
 
Maria Lindberg   Pernilla Albinsson          Veronica Svedhem-Johansson 
Nurse    Nurse                     Senior Physician 
08-524 839 20   08-58580000   08-58580000 
 
Principal Investigator is Lars E. Eriksson, associate professor, Department of 
Neurobiology Care Sciences and Society, Division of Nursing, Karolinska Institutet, 
lars.eriksson@ki.se 
 
Consent for participation in the study Living with long-term infections. 
We here ask for your consent to participate in the study and to compile the answers 
from the questions with data from your medical records. All responses are 
anonymous. 
 
 
 
Date:___________________      
Signature:__________________________________________                             
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11.3 APPENDIX 3 – A PROPOSED 16-ITEM HIV STIGMA SCALE  
Experiences from living with HIV 
This study asks about some of the social and emotional aspects of having HIV. For most 
of the questions, just circle the letters or numbers that go with your answer. There is no 
right or wrong answers. Feel free to write in comments as you go through the questions.  
Please do your best to answer each question.  
For each item, circle your answer: Strongly disagree (SD), disagree (D), agree (A), strongly 
agree (SA) or not applicable (NA). 
 
 
 
 
 Strongly   
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
Not 
applicable 
(NA) 
2. I feel guilty because I 
have HIV 
SD D A SA NA 
3. People’s attitudes about 
HIV make me feel worse 
about myself 
SD D A SA NA 
4. Telling someone I have 
HIV is risky 
SD D A SA NA 
6. I work hard to keep my 
HIV a secret 
SD D A SA NA 
7. I feel I am not as good a 
person as others because I 
have HIV 
SD D A SA NA 
9. People with HIV are 
treated like outcasts 
SD D A SA NA 
10. Most people believe that 
a person who has HIV is 
dirty 
SD D A SA NA 
14.  Most people think that a 
person with HIV is 
disgusting 
SD D A SA NA 
15. Having HIV makes me 
feel like I’m a bad person 
SD D A SA NA 
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 Strongly   
disagree 
(SD) 
Disagree 
 
(D) 
Agree 
 
(A) 
Strongly 
agree 
(SA) 
Not 
applicable 
(NA) 
17. I am very careful who I 
tell that I have HIV 
SD D A SA NA 
20. Most people are 
uncomfortable around 
someone with HIV 
SD D A SA NA 
22. I worry that people may 
judge me when they learn 
I have HIV 
SD D A SA NA 
28. Some people avoid 
touching me once they 
know I have HIV 
SD D A SA NA 
29. People I care about 
stopped calling after 
learning I have HIV 
SD D A SA NA 
36. I have lost friends by 
telling them I have HIV 
SD D A SA NA 
39.  People seem afraid of me 
once they learn I have 
HIV 
SD D A SA NA 
 
 
 
 
Item 28, 29, 36, 39 =Personalized stigma 
Item 4, 6, 17, 22 = Disclosure concerns 
Item 9, 10, 14, 20 = Concerns about public attitudes 
Item 2, 3, 7, 15 = Negative self-image 
 
